

Subject Index

A

Abdominal fat, genome-wide scan for, in Québec Family Study, 614
Acetyl-CoA carboxylase, regulation of, in β -cells, 1580
Acarin dysmorphogenesis, by PDX-1 misexpression in exocrine pancreas, 1553
Actin, early glucose adduct formation by, in diabetes, 1666
Activin type 2B receptor gene (*ACVR2B*), diabetes-associated mutations in French patients, 1219
1-Acyl-glycerol-3-phosphate acyltransferase- α , overexpression effects in adipose tissue and skeletal muscle, 233
Adeno-associated virus, islet cell transduction with, 515
Adenosine diphosphate (ADP), free, in insulin-secreting cells, 291
Adenosine monophosphate (AMP)-activated protein kinase activation of in insulin-resistant rats, 1076 in type 2 diabetes, 921 HNF-4 α target, 1515
Adenosine triphosphate (ATP)-sensitive K⁺ channels activation by insulin, in β -cells, 2192 in endocrine pancreas cell survival and differentiation, S48 nicorandil action on, 2253
Adenovirus Av3hGKR, for type 2 diabetes, 1813 early region 3 genes, diabetes decrease by, in NOD mice, 980 glucokinase expression by, phenotypic correction of diabetes by, in mice, 2287
Adenyl cyclase, activity in rat islets, 2505
Adipocyte markers, mRNA levels, bezafibrate and, 1883
Adipocytes differentiation of, inhibition by indinavir, 1378 fatty acid oxidation in, bezafibrate and, 1883 GLUT4 translocation by troglitazone in, in rat, 2296 insulin receptor dephosphorylation in, in rat, 83 lipolysis alterations in, subcellular localization of IRS family proteins and, in mice, 1455 metabolism of, nelfinavir effects on, 1425 MMP-2 and MMP-9 production by, 2080 3T3-L1 metabolism of, nelfinavir effects on, 1425 VEGF mRNA levels, troglitazone treatment effects on, 1166
Adiponectin circulating levels in insulin resistance, in rhesus monkeys, 1126 expression of, PPAR γ ligands and, 2094
Adipose tissue. *see also* Fat AGAT- α overexpression effects in, 233 differentiation of, MMP-2 and MMP-9 effects in, 2080

gene expression regulation by insulin in, in human, 1134 remodeling of, pioglitazone and, 1863
Adiposity. *see also* Obesity HDLs in, in apoA-II transgenic mice, 643 regulatory effects of leptin on, H₁-receptor disruption and, in mice, 385 ADP (adenosine diphosphate), free, in insulin-secreting cells, 291
Adrenal gland, sympathetic activity in, effects of hypoglycemia on, in rats, 1119 α_1 -Adrenergic receptors, blockade, insulin secretion and glucose kinetics during exercise with, 1834 α_2 -Adrenergic receptors, blockade, insulin secretion and glucose kinetics during exercise with, 1834 α_2 -Adrenergic receptors, gene variants, and obesity, in Caucasian women, 91 β_1 -Adrenergic receptors, diabetes effects on expression in rat hearts, 455 β_2 -Adrenergic receptors, diabetes effects on expression in rat hearts, 455 β_3 -Adrenergic receptors agonist AJ-9677, insulin resistance amelioration by, in KK-A'/Ta diabetic obese mouse, 113 expression in heart, diabetes effects on, in rat, 455 gene variants, and obesity, in Caucasian women, 91
 β -Adrenergic receptors, expression in heart, diabetes effects on, in rat, 455 Advanced glycation end-product receptor functional gene promoter polymorphisms, 1505 p38 MAPK-dependent NF- κ B activation, 1495 putative genes, polymorphism screening of, 1214
AGAT- α . *see* 1-Acyl-glycerol-3-phosphate acyltransferase- α
Agouti-related protein chronic, effects in pair-fed animals, 248 mRNA levels, ghrelin effects on, in rat hypothalamus, 2438
AICAR. *see* 5-Aminoimidazole-4-carboxamide-1- β -d-ribofuranoside AJ-9677, insulin resistance amelioration by, in KK-A'/Ta diabetic obese mouse model, 113
Albumin glomerular permeability response to ACE inhibition, 2619 synthesis of, insulin effects on, in swine model, 947 urinary excretion rate, and autonomic neuropathy in nondiabetic offspring of type 2 diabetic subjects, Fredericia Study, 630
Albuminuria, antihypertensive therapy effects on renal structure in type 1 diabetic subjects with, 843
Alcohol consumption, and type 2 diabetes risk among men, 2390
Allogeneic islets, stable, reversal of streptozotocin-induced diabetes with, in type 1 model, 1227
Allorecognition, indirect, in acquired thymic tolerance, 1546
Allorejection, protection of islets against, by barium-alginate membrane, 1698
Allotransplantation, islet, in type 1 diabetes, 277
 α -Cells clonal mouse α TC6 cells, exocytosis of L-glutamate by, 1012 plasma glucose changes and, in dog, 367 α TC6 cells, exocytosis of L-glutamate by, 1012 American Diabetes Association, research funded by, year 2 status, 1222
Amino acids, effects on free ADP in BHC9 insulin-secreting cells, 291 Aminoaciduria, with HNF-1 α mutations, 2047 Aminoguanidine, diabetic retinopathy inhibition by, 1636 5-Aminoimidazole-4-carboxamide-1- β -d-ribofuranoside chronic, effects on insulin-stimulated glucose uptake and GLUT4 translocation, in rat skeletal muscles, 12 effects on glucose and lipid metabolism, in rats, 1076 AMP (adenosine monophosphate)-activated protein kinase activation of in insulin-resistant rats, 1076 in type 2 diabetes, 921 HNF-4 α target, 1515 Amyloidosis, islet characteristics of, 2514 promotion by oophorectomy, in hAPP-transgenic mice, S184 Angiogenesis, stimulation by inhibition of lipid peroxidation, in genetically diabetic mouse, 667 Angiogenic eye disease, pigment epithelial-derived factor loss in, 2641 Angiopoietin-2, induction by angiotensin II, in endothelial cells, 867 Angiotensin II Ang-2 induction by, in endothelial cells, 867 oxidative stress, inhibition by IGF-1 overexpression, 1414 PKC translocation and, 1918 Angiotensin-converting enzyme inhibitors albumin permeability response to, 2619 glomerular lesion modulation by, in diabetic nephropathy, 2619 Animal studies. *see also* specific species pair-fed animals, chronic agouti-related protein and energy expenditure in, 248 pig-to-mouse fetal endocrine pancreas transplantation, differentiation of, 962 type 1 diabetes models, international workshop on lessons from, 2451 Annexin I early glucose adduct formation by, in diabetes, 1666 gene, in type 2 diabetes, 2402

Annexin II, early glucose adduct formation by, in diabetes, 1666

Antibodies. *see* Autoantibodies

Antigen, mucosal, diabetogenic CTL priming by, 771

Antihypertensive therapy, renal structure effects, in type 1 diabetic subjects with albuminuria, 843

Antioxidants

- effects on diabetic retinopathy, 1938
- effects on endoneurial blood flow, motor nerve conduction velocity, and sciatic nerve arterioles, 1927
- and plasma 8-hydroxyguanine levels in diabetic rats, 2837

Apolipoprotein A-II, transgenic mice studies, 643

Apolipoprotein B-48 lipoproteins, plasma, modulation by hyperinsulinism, 462

Apolipoprotein C1, protection from obesity and insulin resistance by, in mice, 2779

Apoptosis

- β -cell, S44
 - Bcl-2 and Bax- Ω downregulation and, in rat, S82
 - in diabetes, S44
 - imidazoline protection against, S70
 - induction by glucose, 1683
 - nuclear factor- κ B and, 2219
 - signaling of, S58
 - in type 1 diabetes, S64
 - in diabetes, S44
 - endothelial, in diabetes, 1472
 - induction by high glucose, in human islets, 1290
 - islet-cell
 - IL-1-induced, 551
 - induction by high glucose, in human cells, 1290
 - modulation by glucose and palmitic acid, in rat cardiomyocytes, 2105
 - myocyte, hyperglycemia and p53 and, 2363
 - vascular smooth muscle cell, glucose metabolism association, 1171
- AR42J cells, differentiation of
 - Na-Pi cotransporter expression during, S39
 - neurogenin 3 in, S10
- Ashkenazi Jews, genome scan for type 2 diabetes loci, 681
- Aspirin, diabetic retinopathy inhibition by, 1636
- Atherosclerosis

 - diabetes-induced, in swine, 1654
 - risk factors, kidney-pancreas transplantation effects on, 496
 - smooth muscle accumulation in, in diabetic subjects, S51

- ATP-sensitive K⁺ channels

 - activation by insulin, in β -cells, 2192
 - in endocrine pancreas cell survival and differentiation, S48
 - nicorandil action on, 2253

- Autoaggressive lymphocytes, protection from, in transgenic mice, 2700
- Autoantibodies

 - anti-CD38, human
 - in Caucasian diabetic subjects, 752
 - signaling properties of, 985
 - GAD65
 - human recombinant, from type 1 diabetes, 1976
 - in ICA+ relatives, 1735
 - insulin, in NOD mice, 2451
 - response to islet transplantation in type 1 diabetes, 2464
 - seroconversion in siblings of children with type 1 diabetes, 2625

- Autoantigen

 - IA-2
 - autoimmunity against, by IA-2 gene splicing in pancreas and lymphoid organs, 895
 - coding and promoter regions of, 2406
 - for T-cell workshops, 1749
 - Autoimmune diabetes
 - decrease by adenovirus genes, in NOD mice, 980
 - Idd5.1* mapping for, in NOD mice, 2874
 - pancreatic biopsy in, 1269
 - transgenic c-Maf effects on, 39

- Autoimmunity

 - β -cell, reversible, in transgenic mice, 2260
 - chromosome 18 and, 184
 - against IA-2 type 1 diabetes autoantigen, by IA-2 gene splicing in pancreas and lymphoid organs, 895

- Autoislet transplantation

 - long-term, 47
 - prevention of diabetes by, after pancreatectomy for chronic pancreatitis, 47

- Autonomic neuropathy, and parental diabetes, Fredericia Study, 630
- Autoreactive T-cells, detection of, in type 1 diabetes, 1749

B

B9-23 peptide, insulin autoantibody induction by, in mice, 1274

Barium currents, nerve growth factor and, 1755

Barium-alginate membrane, protection of islets against allorejection by, 1698

Bax-caspase-3 pathway, p38 MAPK phosphorylation downstream of, endothelial apoptosis and, 1472

Bax- Ω , downregulation of, and rat β -cell apoptosis, S82

BB rat thymocytes, 972, 2414

Bcl-2

- downregulation of, and rat β -cell apoptosis, S82
- in rat blastocysts, 143

Benzylamine, combined with vanadate, in STZ-induced diabetic rats, 2061

β -Cells

- acetyl-CoA carboxylase regulation in, 1580
- adaptation to diabetes, S154
- adaptation to glucose level changes, *c-myc* gene and, S137
- adaptation to hyperglycemia, S180
- adhesion to extracellular matrix, intracellular calcium and, 1039
- apoptosis of, S44
- Bcl-2 and Bax- Ω downregulation and, in rat, S82
- in diabetes, S44
- imidazoline protection against, S70
- induction by glucose, 1683
- nuclear factor- κ B and, 2219
- signaling of, S58
- in type 1 diabetes, S64
- autoimmunity against, reversible, in transgenic mice, 2260
- barium current in, nerve growth factor and, 1755
- cytotoxic damage to, prevention by TIMP-1, 1047
- death of
 - β -cells in, S52

blockade by cell-permeable peptide JNK inhibitors, 77

decompensation in diabetes, S154

-deficient mice, diabetogenic T cells in, 763

development of

- early, in type 2 diabetes, in GK rat model, S84
- IPF-1 and, S36

differentiation of, S55

- induction by GLP-1, 744
- novel pancreatic precursor cell line for study of, S42

dysfunction of

- in IRS-1 Gly972Arg, 882
- PDX1 deficiency and, in *P. obesus*, 1799
- in type 2 diabetes, S160, S169
- in type 2 diabetes, evidence for, S172
- expansion of
 - by EGF, 1571
 - for type 2 diabetes treatment, S189

Fas expression in, molecular regulation of, S83

function of

- fatty acid effects on, 69
- genetic factors, S84
- in GK rat, S89
- IRS proteins and, S140
- metabolic effects of restoration after islet allotransplantation in type 1 diabetes, 277
- metabolic factors, S84
- oral glucose tolerance test minimal model index of, 150
- overstimulation and, S122
- in type 2 diabetes, S140

gene expression monitoring, online, S15

gene expression profiling, S135

gene mutations, pathophysiology of, S101

glucose induction of hormone-sensitive lipase in, 2225

glucose sensing in, 1

glucotoxicity in *P. obesus* type 2 diabetes, S113

growth factors, S25

growth of, S5

- GLP-1-induced, PKC ζ and, 2237
- hyperplasia in *Ius* knockout mice, S150
- IFN- γ signaling in, 2744
- insulin activation of K_{ATP} channels in, 2192
- insulin receptor and, S146
- insulin secretion in
 - BLI1282 and, 797
 - nerve growth factor and, 1755
- Kit* expression in, 2021
- lipolysis in, GLP-1 and, 56
- lipotoxicity of, 315
 - in obesity, S118
- mass decrease in minipig, 2001
- mass in type 2 diabetes, S140
 - preservation of, S188
 - reduction of, S169
- mass in Zucker diabetic fatty rats, 1021
- mass of, in vivo measurement of, in mouse model, 2231

mTOR-signaling pathway translation

- initiation by, regulation by leucine, 353

neogenesis of

- by neonatal GLP-1 treatment, in rats, 1562
- in type 2 diabetes, S186
- neutral lipid synthesis in, 315
- nNOS in, insulin secretion regulation by, 1311, 2177

novel cytokine-induced genes in, identification by high-density oligonucleotide arrays, 909

number in type 2 diabetes, S169
p57^{KIP2} expression in, 2763
 PDX-1 shuttling in, 2344
 plasma glucose changes and, in dog, 367
 recruitment by glucose, 540
 secretory and metabolic pathway genes,
 regulation by glucose, S135
 sorting of, sialylated NCAM (PSA-NCAM)
 for, S125
 -specific insulin and PDX-1 expression,
 S131
 transcription defect in, in ZDF rat, 63
 transcription factor mutations, S94
 turnover of
 assessment and implications, S20
 fatty acid effects on, 69
 genetic and metabolic factors, S84
 UCP-2 overexpression in, 1302
 viability in GK rat, S89
 β Hc9 insulin-secreting cells, free ADP in, 291
 Bezafibrate, and fatty acid oxidation in
 adipocytes, 1883
 Biopsy, pancreatic, in type 1 diabetes, 1269
 Birth weight, diabetes-associated HLA-DQ
 genes and, 2879
 BL11282, and insulin secretion in β -cells, 797
 Blastocysts, Bcl-2 in, in rat, 143
 Blood flow, endoneurial, antioxidant
 treatment and, 1927
 Blood pressure
 diurnal variation, QTc dispersion and, in
 diabetes, 837
 24-h ambulatory, and autonomic neuropathy
 in nondiabetic offspring of type 2
 diabetic subjects, Fredericia Study, 630
 BMI, parent-of-origin effects in, genome-wide
 scan for, 2850
 Body weight
 cerulenin effects on, 733
 ghrelin effects on, in rat, 2438
 Bovine retinal endothelial cells, angiopoietin-2
 induction by AII in, 867
 Brain
 acute hypoglycemia effects on, functional
 MRI study, 1618
 ¹⁸F-FDG uptake at hypoglycemia in, in type
 1 diabetic men, 2329
 glucose transport in, insulin and, 2203
 BRL 49653. *see* Rosiglitazone

C

Caffeine, and glucose disposal, 2349
 Calcium
 coronary artery, familial aggregation of, in
 type 2 diabetic families, 861
 cytoplasmic, in islet cell clusters,
 measurements of, 540
 -dependent exocytosis of l-glutamate by
 α Tc6 cells, 1012
 intracellular
 and β -cell adhesion, 1039
 increase by human anti-CD38
 autoantibodies, 985
 and Rab3A association with calmodulin,
 2029
 Calcium-cycling proteins, and sarcoplasmic
 reticulum dysfunction, in diabetic heart,
 2133
 Calmodulin, association with Rab3A, 2029
 Calpains, regulation of insulin secretion and
 action by, 2013
 Capillary recruitment, insulin-mediated
 exercise training and, in rat, 2659
 in muscle, in hyperinsulinemia, 2682
 CAPN10 gene, UCSNP-43 polymorphism, and
 insulin secretion, 2161

Carbohydrates, metabolism of, liver-derived
 IGF-I and, 1539
 Carbon monoxide, vasorelaxant effects in
 diabetes, 166
 Cardiac surgery, nitric oxide metabolism
 during, diabetes and, 2603
 Cardiomyocytes, dysfunction of, with insulin
 resistance, in sucrose-fed rats, 1186
 Cardiomyopathy
 diabetic, inhibition by IGF-1
 overexpression, 1414
 glucose, 2105
 Carnitine palmitoyltransferase-1, muscle,
 inhibition of, promotion of
 intramyocellular lipid accumulation and
 insulin resistance by, in rats, 123
 CART gene, mutations in obese children, 2157
 Caucasians
 diabetic, anti-CD38 autoantibodies in, 752
 women, adrenoceptor gene variants and
 obesity in, 91
 Caveolin, levels, in hypertensive rats, 2148
 C57BL/6J mice, diabetic embryopathy in, 1193
 CD38, anti-CD38 autoantibodies, human
 in Caucasian diabetic subjects, 752
 signaling properties of, 985
 CD40-CD154 pathway, blockade of, islet graft
 survival prolongation by, in NOD mice,
 270
 CD154
 CD40-CD154 pathway, blockade of, islet
 graft survival prolongation by, in NOD
 mice, 270
 hamster anti-murine mAb MRI, chronic,
 islet graft survival prolongation by, in
 NOD mice, 270
 C/EBP, and Fas regulation by cytokines, 1741
 Cell death. *see* Apoptosis
 Cell differentiation
 AR42J cell
 Na-Pi cotransporter expression during,
 S39
 neurogenin 3 in, S10
 β -cell, S5
 novel pancreatic precursor cell line for
 study of, S42
 endocrine
 ATP-sensitive K⁺ channels in, S48
 in transplanted human islets, 301
 of nestin-positive stem cells from adult
 islets, 521
 pancreatic islet, ATP-sensitive K⁺ channels
 in, S48
 preadipocyte, inhibition by indinavir, 1378
 of transplanted fetal endocrine pancreas, in
 pig-to-mouse model, 962
 Cell growth
 β -cell, S5
 GLP-1-induced, PKC ζ and, 2237
 endocrine, in transplanted human islets, 301
 insulin activation of PKC δ in, 255
 insulin-producing cell, inhibition by STAT5,
 S40
 VSM cell, stimulation by hypoxia, 1482
 Cell proliferation. *see* Cell growth
 Cell-replacement therapy, for type 1 diabetes,
 2181
 Cephalic insulin response to meal ingestion,
 in humans, 1030
 Ceramide, insulin resistance by, 2563
 Cerebellar granule cells, type 1 diabetic serum
 effects on, S77
 Cerebral glucose, insulin and, 2203
 Cerulenin, mechanism of action, 733
 Children, prepubertal, insulin sensitivity and
 fat in, 477

Chinese subjects, with late-onset type 2
 diabetes, IRS-2 gene in, 1949
 Chloride channels, HIT cell volume regulation
 by, 992
 Cholesterol, metabolism of, regulation by
 insulin and leptin, 955
 Cholesterol absorption inhibitors, ezetimibe,
 normalization of combined dyslipidemia
 by, in obese hyperinsulinemic hamsters,
 1330

Chromosome 3
 Idd10 and *Idd18* loci on, mapping by
 genetic interaction, in NOD mice, 2633
 RAGE gene 5' regulatory region, variation
 with chromosome 6 RAGE gene, 2646
 Chromosome 6, RAGE gene on, variation with
 chromosome 3 5' regulatory region, 2646
 Chromosome 18p11, type 2 diabetes loci,
 genome scan for, 675, 1512
 in Ashkenazi Jews, 681
 Chromosome 12q15, type 2 diabetes locus on,
 204
 Chromosome 18q12-q21, association with
 autoimmunity, 184
 Cigarette smoking and microalbuminuria
 onset in type 1 diabetes, 2842
 Circadian variations
 in blood pressure, QTc dispersion and, in
 diabetes, 837
 in glucose tolerance, 1237
 c-Jun NH₂-terminal kinase
 activity in insulin-secreting cells, 2721
 cell-permeable peptide inhibitors of, 77
 Clonal mouse α cells, cTC6 cells, exocytosis
 of l-glutamate by, 1012
 c-Maf, transgenic, effects on autoimmune
 diabetes, 39
 c-myc gene, in β -cell adaptation to glucose
 level changes, S137
 Collagen, platelet activation, induction by
 hyperglycemia, 1491
 α 1(IV) Collagen, ET-1 activation of, high
 glucose-enhanced, in mesangial cells,
 2376
 Combined dyslipidemia, normalization by
 ezetimibe, in obese hyperinsulinemic
 hamsters, 1330
 Complementary DNA arrays, for gene
 identification in suckling rat islets, 2053
 Congenital hyperinsulinism, insulin
 dysregulation in, 322
 Conjugated linoleic acid, antidiabetic
 properties of, 1149
 Contraction
 skeletal muscle, insulin p38 MAPK α and β
 activation and, in rat, 478
 -stimulated glucose transport, inhibition by
 indinavir, in skeletal muscle, 1397
 Copper, Cu²⁺/Zn²⁺ superoxide dismutase,
 protection against early diabetic
 glomerular injury in transgenic mice by,
 2114
 Coronary artery calcium
 familial aggregation of, in type 2 diabetic
 families, 861
 lipid transfer protein activities and, in type
 1 diabetes, 652
 Coronary microvascular dilation, in type 2
 diabetes, 1180
 Corticotropin-releasing hormone, secretion of,
 modulation by galanin, 2666
 Counter-regulatory failure, FDG-PET in, 2329
 C-peptide, stimulation by decreased fasting
 and oral glucose, with SUR1 sequence
 variants, 697

Creatine, oral supplementation, effects on human muscle GLUT4 protein content, 18

CTLA4 gene, point mutation in West African type 1 diabetes patients, 2169

Cyclic stretch, retinal VEGF-R2 expression, 444

Cystic fibrosis, protein metabolism in, 1336

Cytokines

- β-cell apoptosis, Bcl-2 and Bax-Ω downregulation and, in rat, S82
- Fas regulation by, 1741

Cyttoplasmic calcium, in islet cell clusters, measurements of, 540

Cytotoxic T-lymphocytes, diabetogenic, priming by mucosal antigen, 771

Cytotoxicity

- free fatty acid, in islet cells, 1771
- islet, prevention by TIMP-1, 1047

D

Daily rhythms

- in blood pressure, QTc dispersion and, in diabetes, 837
- in glucose tolerance, 1237

Decompensation, β-cell, in diabetes, S154

Dendritic cells, allopeptide-primed, tolerance by, 1546

2-Deoxy-d-glucose, abolishment of glucoprivic responses by, 2831

Dephosphorylation, insulin receptor, in rat adipocytes, 83

Dexamethasone, abolishment of glucoprivic responses by, 2831

Diabetes

- accelerated atherosclerosis with, in swine, 1654
- amelioration by GLUT4 overexpression, in *db/db* mice, 593
- animal models. *see Animal studies; specific animals*
- apoptosis in, S44
- autoimmune
 - Idd5.1* mapping for, in NOD mice, 2874
 - transgenic c-Maf effects on, 39
- β-adrenoceptor expression in rat hearts with, 455
- β-cell adaptation to, S154
- β-cell death in, S44
- β-cell decompensation in, S154
- β-cell mass in, *in vivo* measurement of, in mouse model, 2231
- decrease by adenovirus genes, in NOD mice, 980
- endothelial apoptosis in, 1472
- endothelial plasma membrane glycation in, 1666
- lipoatrophic, rescue by transgenic leptin, in mouse model, 1440, 1675
- maternal, altered nephrogenesis due to, IGF-II/M6PR in, 1069
- maternity-onset
 - associated *ACVR2B* mutations, in French patients, 1219
 - NEUROG3* mutations and, in Japanese subjects, 694
- microencapsulated islet survival in, in NOD mice, 1698
- natural killer T-cell deficiency in, in NOD mice, 2691
- and nitric oxide during cardiac surgery, 2603
- parental, autonomic neuropathy and, Fredericia Study, 630
- phenotypic correction by adenoviral glucokinase expression, in mice, 2287

phogrin T-cell epitopes in, in NOD mice, 1729

PKC ϵ overexpression in skeletal muscle before, 584

polymorphic studies in, 2646

prevention by autoislet transplantation after pancreatectomy for chronic pancreatitis, 47

resistance to, PPAR-γ Ala¹² variant and, 891

retinal metabolism in, 1938

sarcoplasmic reticulum dysfunction in, 2133

smooth muscle accumulation in atherosclerotic lesions with, 851

SREBP-1c and glucose homeostasis in mice with, 2425

streptozotocin-induced plasma 8-hydroxyguanine levels in, in rats, 2837

reduction by metallothionein, 2040

reversal with stable allogeneic islet function, in type 1 model, 1227

sustained NF-κB activation associated with, 2792

type 1. *see Type 1 diabetes*

type 2. *see Type 2 diabetes*

vasorelaxant effects of CO in, 166

Diabetes Prevention Trial-Type 1, eligibility for, GAD65 autoantibodies in ICA+ relatives and, 1735

Diabetic cardiomyopathy, inhibition by IGF-I overexpression, 1414

Diabetic embriopathy, in C57BL/6J mice, 1193

Diabetic heart, insulin signaling in, in rat, 2709

Diabetic nephropathy

- candidate gene screening in, 1214
- glomerular lesions in, modulation by ACE inhibitors, 2619

Diabetic neuropathy, vascular dysfunction in, 1927

Diabetic retinopathy

- antioxidant effects on, 1938
- functional RAGE promoter polymorphisms and, 1505
- IGF-I signaling in, 175
- inhibition by aminoguanidine and aspirin, 1636
- microthromboses in, 1432

Diabetogenic T cells

- in β-cell-deficient mice, 763
- cytotoxic, priming by mucosal antigen, 771

Diet

- high-fat, -induced insulin resistance, in PPAR-α-null mice, 2809
- induced type 2 diabetes, rebred Cohen rat model of, 2521

Dilation, coronary vasodilation, in type 2 diabetes, 1180

Dipeptidyl peptidase IV, inhibition of, and glucose-dependent insulinotropic peptide, in pigs, 1588

Diurnal variations

- in blood pressure, QTc dispersion and, in diabetes, 837
- in glucose tolerance, 1237

Dog studies

- α- and β-cell responses to non-insulin-induced hypoglycemia in, 367
- denervated pancreas response to mild hypoglycemia, 2487
- low-dose insulin and hypoglycemia in, 558

Dopamine receptor D2 gene, Ser311Cys mutation, and energy expenditure, 901

Drinking patterns, and type 2 diabetes risk among men, 2390

Dyslipidemia

combined, normalization by ezetimibe, in obese hyperinsulinemic hamsters, 1330

of insulin resistance, hepatic proteoglycans and, 2126

E

Early response genes. *see specific genes*

Edmonton protocol, islet transplantation with, outcomes and insulin secretion after, 710

Efaroxan, insulin secretion potentiation by, K_{ATP} channel-independent, 340

Elderly, inflammation markers and glucose disorders in, 2384

Electrocardiography, QTc dispersion, and diurnal BP variations, in diabetes, 837

Embryonic cells, pancreatic, expansion by EGF, 1571

Embryonic stem cells, insulin production by, 1691

Embryopathy, diabetic, in C57BL/6J mice, 1193

Endocrine cells, proliferation and differentiation in transplanted human islets, 301

Endocrine pancreas

- cell survival and differentiation, ATP-sensitive K⁺ channels in, S48
- fecal, ontogeny of, 962
- in insulin receptor-deficient mouse pups, S146
- nestin-positive stem cell differentiation into, from adult islets, 521
- plasticity of, S30
- transplanted fetal, differentiation of, in pig-to-mouse model, 962

Endoneurial blood flow, antioxidant treatment and, 1927

Endothelial cells

- angiopoietin-2 induction by AII in, 867
- apoptosis of, in diabetes, 1472
- glycated LDL uptake in, mediation by lipoprotein lipase, 1643

Endothelial dysfunction, induction in obesity, 159

Endothelial function

- insulin-stimulated, in type 2 diabetic patients with ischemic heart disease, 2611
- kidney-pancreas transplantation effects on, 496

Endothelial insulin resistance, in type 2 diabetic patients with ischemic heart disease, 2611

Endothelial plasma membrane glycation, in diabetes, 1666

Endothelin-1, ERK1/2 and α1(IV) collagen activation by, high glucose-enhanced, in mesangial cells, 2376

Energy expenditure

- chronic agouti-related protein and, in pair-fed animals, 248

DRD2 gene and, 901

Energy fuels, channeling toward fat vs muscle during high free fatty acid availability, in rats, 601

Epidermal growth factor

- oral wound healing reversal by, in NOD mice, 2100
- pancreatic embryonic cell expansion by, 1571

European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT), antihypertensive therapy effects on renal structure in type 1 diabetes with albuminuria, 843

Exercise

AMPK activation during, in type 2 diabetes, 921
 bicycle, effects on GSK3 regulation in skeletal muscle, 265
 glucose kinetics during
 glucosamine and, in rats, 139
 insulin secretion and, 1834
 resistance to, in insulin-resistant skeletal muscle, in type 1 diabetes, 1371
 Exercise training, and insulin action, in rat, 2659
E
 Exocrine pancreas
 monocarboxylate transporter expression and distribution in, 361
 nestin-positive stem cell differentiation into, from adult islets, 521
 PDX-1 misexpression in, glucose tolerance and acinar dysmorphogenesis by, 1553
 Extracellular matrix, β -cell adhesion to, intracellular calcium and, 1039
 Extracellular signal-regulated protein kinase ERK1/2, ET-1 activation of, high glucose-enhanced, in mesangial cells, 2376
 Eye disease, angiogenic, pigment epithelium-derived factor loss in, 2641
 Ezetimibe, normalization of combined dyslipidemia by, in obese hyperinsulinemic hamsters, 1330

F
 Familial combined hyperlipidemia, gene effects on insulin sensitivity in, 2396
 Families
 siblings of type 1 diabetic children, autoantibody seroconversions in, 2625
 with type 2 diabetes
 familial aggregation of coronary artery calcium in, 861
 GIP insulinotropic effects in, 2497
 glucose-intolerant relatives, skeletal muscle insulin signaling in, 2770
 insulin receptor signaling in, 2572
 lactate release per fat cell in, 2344
 Fas
 expression in β -cells, molecular regulation of, S83
 function in polyreactive type 1 diabetes, 483
 regulation by cytokines, 1741
 Fas receptor, upregulation by glucose, 1683
 Fasting
 decreased, C-peptide stimulation by, with SUR1 sequence variants, 697
 protein-retaining effects of growth hormone during, 96
 Fasting insulin, gene effects on, in familial combined hyperlipidemia, 2396
 Fat. *see also* Adipose tissue
 abdominal, genome-wide scan for, in Québec Family Study, 614
 accumulation of reduction by central histamine infusion, in leptin-resistant obese mice, 377
 gene expression in, nonesterified fatty acids and, in rats, 601
 high-fat
 -induced insulin resistance, in PPAR- α -null mice, 2809
 insulin signaling in muscle in rats on, 1901
 insulin sensitivity and, in prepubertal children, 477
 intramyocellular content, plasma FFAs and, 1612
 lactate release per cell, in type 2 diabetic relatives, 2344
 omental, gene expression profiling of, 2822
 Fatty acids. *see also* Free fatty acids
 effects on β -cell turnover and function, 69
 -induced peripheral tissue insulin resistance, susceptibility to, in women, 1344
 and liver proteoglycans, 2126
 metabolism in insulin-resistant muscle of Zucker diabetic fatty rats, 1389
 nonesterified, and gene expression, in fat and muscle, in rats, 601
 oxidation in adipocytes, bezafibrate and, 1883
 regulatory effects on macrophage lipoprotein lipase, 660
 spillover of, causes of, β -cell lipotoxicity in, S118
 uptake in insulin-resistant muscle of Zucker diabetic fatty rats, 1389
 Fatty liver disease, nonalcoholic, 1844
 Feeding
 high-sucrose, neuropeptide Y overexpression and obesity after, 1206
 regulatory effects of leptin on, H₁-receptor disruption and, in mice, 385
 Fetal endocrine pancreas
 ontogeny of, 962
 transplanted, differentiation of, in pig-to-mouse model, 962
 Fetal kidney, diabetes-impaired, IGF-II/M6PR in, 1069
 Fetal sex ratio, in C57BL/6J mice, 1193
 Fibrinogen, synthesis of, insulin effects on, in swine model, 947
 Fibroblasts, glycated LDL uptake in, mediation by lipoprotein lipase, 1643
 Fibronectin, synthesis of, hexosamines and, in mesangial cells, 2355
 Finnish subjects, with late-onset type 2 diabetes, IRS-2 gene in, 1949
 Fizz3, expression in humans, 2199
 Flotillin, levels in hypertensive rats, 2148
¹⁸F-Fluorodeoxyglucose, uptake at hypoglycemia in type 1 diabetic men, 2329
 Food intake
 cerulenin effects on, 733
 effects on GSK3 regulation in skeletal muscle, 265
 Fredericia Study, autonomic neuropathy and parental diabetes, 630
 Free fatty acids
 cytotoxicity of, in islet cells, 1771
 effects on gluconeogenesis, in type 2 diabetes, 810
 effects on insulin secretion and sensitivity in PPAR- γ 2 Pro12Ala, 1143
 effects on intramyocellular fat content, 1612
 effects on splanchnic glucose uptake, in men, 727
 and GH-induced insulin resistance, 2301
 high availability, energy fuel channeling toward fat *vs* muscle during, in rats, 601
 insulin resistance by prevention by thiazolidinedione, in male Wistar rats, 2316
 in rats, 418
 plasma uptake and oxidation in subjects at high-risk for type 2 diabetes, 2548
 plasma-adipose tissue exchange capacity, thiazolidinedione effects on, 1158
 systemic availability of, insulin-mediated control of, thiazolidinedione effects on, 1158
 and UCP2, in insulin secretion, 803
 French patients, diabetes-associated ACVR2B mutations in, 1219
 Fructosamine-3-kinase, human, 2139
 Fructose, stimulation of hepatic glycogen synthesis by, in humans, 1263
 Fusion proteins, transduction of islets with, 1706

G
 GAD65, preparation for detection of autoreactive T-cells, in type 1 diabetes, 1749
 GAD65 autoantibodies
 human recombinant, from type 1 diabetes, 1976
 in ICA+ relatives, 1735
 Galactosemia, retinal metabolism in, 1938
 Galanin, corticotropin-releasing hormone and neuropeptide Y secretion modulation by, 2666
 Gamma globulin, levels, and type 2 diabetes, in Pima Indian population, 1598
 Ganglion neurons, intrapancreatic, modulation of insulin pulses by, 51
 Gastric inhibitory polypeptide, insulinotropic effects in type 2 diabetic patient relatives, 2497
 Gene expression
 β -cell
 expression profiling, S135
 online monitoring of, S15
 in fat and muscle, nonesterified fatty acids and, in rats, 601
 hepatic, leptin and, in obese mice, 2268
 insulin, glucose-regulated, and PDX-1 deficiency, in *P. obesus* type 2 diabetes, S138
 regulation by insulin, in human skeletal muscle and adipose tissue, 1134
 in sucking rat islets, 2053
 tetracycline-inducible (Tet-On), in MIN6 cells, S133
 Gene expression profiling, of omental fat, 2822
 Gene mutations. *see also* Mutations
 Gene polymorphism.
 adrenocorticotropin variants, and obesity, in Caucasian women, 91
 CAPN10 UCSNP-43, and insulin secretion, 2161
GYS1 XbaI, and skeletal muscle glycogen synthase content, 195
 HSL16, and lipolytic function, 2410
 IGF-I, 637
 single nucleotide
 CAPN10 UCSNP-43, and insulin secretion, 2161
 of PC-1, in insulin resistance, 1952
 Gene therapy, for type 1 diabetes, 2181
 Gene transcription, defect in ZDF rat β -cells, 63
 Genes
 β -cell
 novel cytokine-induced, identification by high-density oligonucleotide arrays, 909
 regulation by glucose, S135
 diabetes-associated HLA-DQ, and birth weight, 2879
 in glucose-stimulated insulin secretion, S134
 HDL, transcriptional regulation by glucose, 1850
 p53-related, activation by hyperglycemia, 2363
 Genetic interaction, *Idd10* and *Idd18* mapping by, in NOD mice, 2633

Genetics

- of β -cell function and turnover, S84
- candidate gene screening in diabetic nephropathy, 1214
- of HbA_{1c} levels in type 1 diabetes, 2858
- of insulin resistance in polycystic ovary syndrome, 2164
- of insulin sensitivity in familial combined hyperlipidemia, 2396
- Genome-wide linkage analysis, for parent-of-origin effects, 2850
- GFAT1. *see* Glutamine:fructose-6-phosphate amidotransferase-1
- Ghrelin

 - circulating levels in obesity, 707
 - hyperphagia and obesity caused by, in rats, 2540
 - hypothalamic effects in rats, 2438
 - hypothalamic NPY/Y1 receptor pathway activation by, 227
 - plasma levels, preprandial surges, 1714

- GIP. *see* Glucose-dependent insulinotropic polypeptide
- GK. *see* Glucokinase
- Gliclazide, and pulsatile insulin secretion, in type 2 diabetes, 1778
- Glomerular injury

 - early diabetic, SOD-1 protection against, in transgenic mice, 2114
 - lesions, modulation by ACE inhibitors, in diabetic nephropathy, 2619

- Glomerulus, albumin permeability in response to ACE inhibition, 2619
- Glucagon, secretion of, regulation by GLUT2-dependent sensors, 1282
- Glucagon-like peptide-1

 - β -cell differentiation induction by, 784
 - β -cell growth induced by, PKC ζ and, 2237
 - and β -cell lipolysis, 51
 - and hepatoportal vein glucose sensing, 1720
 - neonatal treatment, β -cell neogenesis by, in rats, 1562
 - postprandial levels, in type 2 diabetes, 609
 - and pulsatile insulin secretion, in type 2 diabetes, 776

- Glucagon-like peptide-1 derivative NN2211, weight loss therapy with, 2530
- Glucagon-like peptide-1(7-36)-amide, effects in type 1 diabetes, 565
- Glucokinase

 - adenoviral, phenotypic correction of diabetes by, in mice, 2287
 - gene locus transgenic mice, resistance to obesity-induced type 2 diabetes in, 622
 - hepatocyte activity, in type 2 diabetes, 1351
 - increased, prevention of type 2 diabetes by, 622
 - mutations, pathophysiology of, S101
 - Glucokinase regulatory protein, adenoviral Av3hGKRP, for type 2 diabetes, 1813
 - Gluconeogenesis

 - free fatty acid effects on, in type 2 diabetes, 810
 - hyperinsulinemia effects on, 1807
 - in small intestine, in rat, 740

 - Glucoparivation, responses to, 2DG or dexamethasone abolishment of, 2831
 - Glucosamine, and exercise-stimulated glucose turnover, in rats, 139
 - Glucose

 - apoptosis induction by in β -cells, 1683
 - in human islets, 1290
 - in rat cardiomyocytes, 2105
 - autoregulation of, free fatty acid effects on, in type 2 diabetes, 810
 - β -cell adaptation to changes in level of, c-myc gene and, S137
 - β -cell recruitment by, 540
 - β -cell secretory and metabolic pathway gene regulation by, S135
 - cerebral levels, 2203
 - disappearance constant, 690
 - disposal of, 2349
 - early adduct formation by endothelial plasmalemma-associated proteins, in diabetes, 1666
 - endogenous production of, suppression of, insulin sensitivity of, 1449
 - during exercise, 1834
 - exercise-stimulated turnover of, glucosamine and, in rats, 139
 - Fas receptor upregulation by, 1683
 - free ADP effects in β HIC9 insulin-secreting cells, 291
 - glycogen synthesis regulation by, in human muscle cells, 720
 - growth-promoting effects in diabetic subjects, 851
 - HDL gene transcription regulation by, 1850
 - hepatoportal vein sensing of, GLP-1 and, 1720
 - high glucose-enhanced ET-1 activation of ERK1/2 and α 1(IV) collagen, in mesangial cells, 2376
 - homeostasis of, SREBP-1c and, in diabetic mice, 2425
 - hormone-sensitive lipase induction by, in β -cells, 2225
 - insulin gene expression regulated by, and PDX-1 deficiency, in *P. obesus* type 2 diabetes, S138
 - insulin secretion induced by

 - free fatty acids and UCP2 in, 803
 - genes in, identification of, S134
 - hormone-sensitive lipase role in, 1970 model for, S164
 - and lipid metabolism, 1402

 - metabolism of

 - AICAR effects on, in rats, 1076
 - hepatic, insulin effects on, 1872
 - IGFBP-1 phosphorylation and, in IGFBP-1 transgenic mice, 32
 - and pulsatile insulin release, 1785
 - renal, in humans, 747
 - and SUR1 sequence variants, 697
 - and VSMC apoptosis, 1171

 - myofibril degeneration induction by, in rat cardiomyocytes, 2105
 - oral, C-peptide stimulation by, with SUR1 sequence variants, 697
 - PKC activation by, angiotensin II and, 1918 plasma

 - α -cell responses to, in dog, 367
 - β -cell responses to, in dog, 367
 - decrease by tramadol, in diabetic rats, 2815

 - renal handling in hypoglycemia, 2087
 - renal release of, measurements of, 905
 - skin keratinocyte effects, 1627
 - uptake of

 - exercise-induced, resistance to, in insulin-resistant skeletal muscle, in type 1 diabetes, 1371
 - insulin-stimulated, effects of chronic AICAR treatment on, in rat skeletal muscles, 12

 - NO-stimulated, in rat skeletal muscle, 241
 - regulation by p38 MAPK, 1464
 - splanchnic

 - free fatty acid effects on, in men, 727
 - GLP-1 effects on, in type 1 diabetes,

565

in type 2 diabetes, 1351

stimulation by α -lipoic acid, 1464**D-Glucose**, high exposure to, Bcl-2 in rat blastocysts after, 143**Glucose disorders**, inflammation markers and, in elderly, 2384**Glucose sensing****Glucose tolerance**. *see also* Oral glucose tolerance test**Glucose transport****PED/PEA-15** effects on, mediation by PKC- α , in L6 skeletal muscle cells, 1244 in skeletal muscle, in hypertensive rats, 2148**Glucose transporter 2**, glucagon secretion regulation by, 1282**Glucose transporter 4**

human muscle, oral creatine supplementation and, 18

overexpression effects, in db/db mice, 593 in slow muscle fibers, in type 2 diabetes, 1324

translocation

Glucose-dependent insulinotropic peptide, dipeptidyl peptidase IV inhibition and, in pigs, 1588**Glucose-dependent insulinotropic polypeptide**, postprandial levels, in type 2 diabetes, 609**Glucose-dependent insulinotropic polypeptide receptor**, expression of, in diabetic fatty Zucker rats, 1004**Glucose-intolerant relatives**, with type 2 diabetes, skeletal muscle insulin signaling in, 2770**Glucosensing neurons**, in ventromedial hypothalamic nucleus, 2673**Glucosidase**-6-phosphatase

mechanism of, 1531

reduction by GSK-3 inhibitors, 937

substrate-transport model of, novel arguments in favor of, 1531

Glucose-sensitive neurons, orexin A excitement of, in rat hypothalamus, 2431

Glucotoxicity, β -cell, in *P. obesus* type 2 diabetes, S113

GLUT. *see* Glucose transporter

L-Glutamate, Ca^{2+} -dependent exocytosis of, by αTcB cells, 1612

Glutamate-sensitive protein phosphatase, acetyl-CoA carboxylase activation by, in β -cells, 1580

Glutamine:fructose-6-phosphate amidotransferase-1, muscle-selective expression, 2419

Glycemia effects on hepatic glycogen metabolism in type 1 diabetes, 392 postprandial, cephalic insulin response to meal ingestion and, in humans, 1030

Glycerol, proinsulin biosynthesis by, in rat islets, 1791

Glycogen glycogen synthesis regulation by, in human muscle cells, 720 metabolism of hepatic stimulation by fructose, in humans, 1263 in type 1 diabetes, 392 insulin effects on, 1872 synthesis of inhibition by palmitate, 2210 regulation by glucose, glycogen, and insulin, in human muscle cells, 720

Glycogen synthase, skeletal muscle content, *GYS1 XbaI* gene polymorphism and, 195

Glycogen synthase gene *GYS1 XbaI* gene polymorphism, and skeletal muscle glycogen synthase content, 195

Glycogen synthase kinase-3, regulation of, in skeletal muscle, 265

Glycogen synthase kinase-3 inhibitors, and type 2 diabetes, 937

Glycogen synthase kinase-3 β , effects in glucose metabolism coupling with VSMC apoptosis, 1171

Growth factors, β -cell, S25

Growth hormone -induced insulin-producing cell proliferation, inhibition by STAT5, S40 insulin resistance induction by, 1891 free fatty acids and, 2301 protein-retaining effects during fasting, 96

GSN. *see* Glucose-sensitive neurons

H

Hamster studies anti-murine hamster mAb MR1, chronic, islet graft survival prolongation by, in NOD mice, 270

obese hyperinsulinemic hamsters, combined dyslipidemia in, normalization by ezetimibe, 1330

Heme oxygenase-1, induction of, and islet graft function, 1983

HbA_{1c}, levels in type 1 diabetes, 2858

HDL. *see* High-density lipoprotein

Heart, diabetic β -adrenoceptor expression in, in rat, 455 disease inhibition by IGF-1 overexpression, 1414 insulin signaling in, in rat, 2709 with ischemic heart disease, endothelial insulin resistance in, 2611 sarcoplasmic reticulum dysfunction in, 2133

Heart surgery, diabetes and nitric oxide metabolism during, 2603

Hepatic artery, detection of hypoglycemia in, 399

Hepatic nuclear factor-1 α , mutations, pathophysiology of, S101

Hepatic phenotypes, differentiation of nestin-positive stem cells from adult islets into, 521

Hepatic steatosis, G6Pase inhibition and, 2591

Hepatocyte growth factor, effects on islet function and transplantation outcomes in mice, 2752

Hepatocyte nuclear factor-1 α mutations, aminoaciduria with, 2047 and pancreatic islet development and metabolism, 2472

Hepatocyte nuclear factor-4 α , AMPK targeting, 1515

Hepatoportal vein, glucose sensing of, GLP-1 and, 1720

HepG2 cells, insulin-mediated PAI-1 signal transduction in, 1522

Hexokinase, isozyme distribution in human skeletal muscle, 1253

Hexosamines and fibronectin synthesis, in mesangial cells, 2355 insulin resistance and, in rats, 418

High-density lipoprotein effects in adiposity and insulin resistance, in apoA-II transgenic mice, 643 transcriptional regulation by glucose, 1850

High-density oligonucleotide arrays, identification of novel cytokine-induced genes in β -cells by, 909

Histamine, central infusion of, in leptin-resistant obese mice, 377

Histamine H₁-receptor, disruption of, and leptin regulatory effects, in mice, 385

HIT cell volume, regulation by chloride channels, 992

Homeobox. *see* Pancreatic duodenal homeobox-1

Hormonal regulation, of β -cell mass, S25

Hormone-sensitive lipase glucose induction of, in β -cells, 2225 in glucose-stimulated insulin secretion, 1970

HSL6 gene polymorphism, and lipolytic function, 2410

HSL. *see* Hormone-sensitive lipase

Human lymphocyte antigen *HLA-DPB1*, and type 1 diabetes, 1200

Human lymphocyte antigen HLA-DQ, diabetes-associated genes, and birth weight, 2879

Human yolk sac, insulin imprinting in, 199

8-Hydroxyguanine, plasma levels, in diabetic rat, 2837

Hyperglucagonemia, β -cell mass decrease and, in minipig, 2001

Hyperglycemia β -cell adaptation to, S180 and increased islet TAG content, in Zucker diabetic fatty rats, 2481

and insulin gene mRNA levels, in Zucker diabetic fatty rats, 2481

and insulin release in GK rat islets, S108

insulin resistance in, insulin receptor dephosphorylation in, in rat adipocytes, 83

and microalbuminuria onset in type 1 diabetes, 2842

p53 activation by, 2363

PKC ϵ overexpression in skeletal muscle before, 584

platelet activation induction by, 1491 and VSM cell growth stimulation by hypoxia, 1482

Hyperinsulinemia capillary recruitment by insulin in muscle in, 2682 clamp in lipoprotein lipase-transgenic mice, and gluconeogenesis, 1807

PKC ϵ overexpression in skeletal muscle before, 584

resistance to exercise-induced glucose uptake in insulin-resistant skeletal muscle during, in type 1 diabetes, 1371

Hyperinsinemic hypoglycemia of infancy, persistent, focal, S182

Hyperinsulinism acute, plasma apoB-48 lipoprotein modulation by, 462 congenital, insulin dysregulation in, 322 of infancy, 329 p57^{KIP2} expression in β -cells in, 2763

Hyperlipidemia, familial combined, gene effects on insulin sensitivity in, 2396

Hyperphagia, caused by ghrelin, in rats, 2540

Hyperplasia, reversible β -cell autoimmunity and, in transgenic mice, 2260

Hypertension muscle glucose transport in, in rats, 2148 retinal VEGF-R2 expression in, 444

Hypoglycemia acute, effects on brain, functional MRI study, 1618 and adrenal sympathetic activity, in rats, 1119 blood-to-brain glucose transport after, 1911 detection of, in hepatic artery or liver, 399 ¹⁸F-FDG uptake at, in type 1 diabetic men, 2329 hypothalamic orexin-B level increase by, 105 low-dose insulin and, in dog, 558 mild, pancreatic response to, 2487 non-insulin-induced α -cell responses to, in dog, 367 β -cell responses to, in dog, 367 orexin neuron activation by, 105 persistent hyperinsinemic of infancy, focal, S182 portal vein glucosensor locus for confirmation of, 399 renal glucose handling in, 2087

Hypothalamic nucleus, ventromedial, glucosensing neurons in, 2673

Hypothalamus ghrelin effects on, in rat, 2438 glucose-sensitive neurons, orexin A excitement of, in rat, 2431 neuropeptide Y/Y1 receptor pathway, activation by ghrelin, 227 orexin B levels, increase by hypoglycemia, 105

Hypoxia, VSM cell growth stimulation by, 1482

I

IA-2. *see* Insulinoma-associated tyrosine phosphatase-like protein

Idd5.1 gene locus, mapping of, for autoimmune diabetes in NOD mice, 2874

Idd10 gene locus, mapping by genetic interaction, in NOD mouse, 2633

Idd18 gene locus, mapping by genetic interaction, in NOD mouse, 2633

IDDM1 gene locus, *HLA-DPB1*-associated component of, and type 1 diabetes, 1200

IDX-1. *see* Islet duodenal homeobox-1
 IGRP. *see* Islet-specific glucose-6-phosphatase catalytic subunit-related protein gene promoter
 imidazoline novel compound BL11282, and insulin secretion in β -cells, 797
 protection against β -cell apoptosis, S70
In situ footprinting, of mouse IGRP gene promoter, 502
 Indinavir glucose transport inhibition by, in skeletal muscle, 1397
 insulin resistance and, 1397
 preadipocyte differentiation inhibition by, 1378
 Infancy hyperinsulinism of, 329
 p57^{KIP2} expression in β -cells in, 2763
 persistent hyperinsulinemic hypoglycemia of, focal, S182
 Inflammation markers, and glucose disorders, in elderly, 2384
 Injury, glomerular, early diabetic, SOD-1 protection against, in transgenic mice, 2114
In knockout mice, β -cell hyperplasia in, S150
 Insulin activity exercise training and, in rat, 2659
 GLP-1 effects on, in type 1 diabetes, 565
 regulation by calpains, 2013
 in skeletal muscle, with conjugated linoleic acid, 1149
 systemic versus portal delivery effects on, in pancreas transplantation, 1402
 TNF- α effects on, in human muscle, 1102
 autoantibodies induction by B9-23, in mice, 1274
 in NOD mice, 2451
 and brain glucose transport, 2203
 capillary recruitment by exercise training and, in rat, 2659
 in muscle, in hyperinsulinemia, 2682
 delivery of, systemic versus portal effects on insulin action and VLDL metabolism, in pancreas transplantation, 1402
 dysregulation in congenital hyperinsulinism, 322
 exocytosis of, calmodulin-Rab3A association and, 2029
 expression of β -cell-specific, S131
 glucose-regulated, and PDX-1 deficiency, in *P. obesus* type 2 diabetes, S138
 fasting, gene effects on, in familial combined hyperlipidemia, 2396
 and glycogen metabolism, 1872
 hepatic activity, in obese type 2 diabetes, 1363
 and hepatic glucose production, 1872
 and hepatic protein synthesis rates, in swine model, 947
 and hepatic proteoglycans, 2126
 in human yolk sac, 199
 K_{ATP} channel activation by, in β -cells, 2192
 low-dose, and hypoglycemia, in dog, 558
 mRNA levels, hyperglycemia and, in Zucker diabetic fatty rats, 2481
 p38 MAPKs and β activation by, and rat skeletal muscle contraction, 478
 PAI-1 signal transduction mediation by, in HepG2 cells, 1522
 PKC δ activation by, in proliferation, 255

and plasma 8-hydroxyguanine levels in diabetic rats, 2837
 postprandial cephalic response, in humans, 1030
 postprandial hepatic clearance, β -cell mass decrease and, in minipig, 2001
 production by embryonic stem cells, 1691
 regulation of, model for, S178
 regulation of cholesterol metabolism by, 955
 regulation of gene expression by, in human skeletal muscle and adipose tissue, 1134
 regulation of glycogen synthesis by, in human muscle cells, 720
 regulation of mitochondrial and cytoplasmic protein synthetic rates by, 2652
 secretion of assessment of, model for, S178
 BL11282 and, in β -cells, 797
 CAPN10 UCSNP-43 polymorphism and, 2161
 during exercise, 1834
 free fatty acid effects on, 803
 in PPAR- γ_2 Pro12A1a, 1143
 in GK rat islets, S108
 glucose-stimulated genes in identification of, S134
 hormone-sensitive lipase role in, 1970 model for, S164
 in HSL-deficient mice, 1970
 in hyperinsulinism of infancy, 329
 IRS-1 Gly972Arg and, 882
 after islet transplantation, 710
 nerve growth factor and, 1755
 p85 α variants and, 690
 in Pima Indians, 1828
 plasma leptin and, 348
 potentiation by efaroxan, K_{ATP} channel-independent, 340
 PPAR- γ Ala¹² variant and, in type 2 diabetes, 891
 pulsatile β -cell mass decrease and, in minipig, 2001
 GLP-1 and, in type 2 diabetes, 776
 glucose metabolism and, 1785
 modulation by intrapancreatic ganglion neurons, 51
 sulfonylurea and, in type 2 diabetes, 1778
 regulation by β -cell neuronal nNOS, 1311, 2177
 regulation by calpains, 2013
 rosiglitazone effects on, 2598
 stimulation by anti-CD38 autoantibodies, in human islets, 985
 swelling-induced, 992
 in type 2 diabetes, S169
 PPAR- γ Ala¹² variant and, 891
 UCP2 effects on, 803
 signaling in diabetic heart, in rat, 2709
 signaling in high fat-fed rat muscle, 1901
 signaling in skeletal muscle, in glucose-intolerant relatives with type 2 diabetes, 2770
 -stimulated endothelial function, in type 2 diabetic patients with ischemic heart disease, 2611
 -stimulated glucose transport, inhibition by indinavir, in skeletal muscle, 1397
 -stimulated glucose uptake, effects of chronic AICAR treatment on, in rat skeletal muscles, 12
 in vivo signaling, p85 α variants and, 691
 Insulin promoter factor-1, and β -cell development, S36
 Insulin receptor and β -cells, S146
 dephosphorylation, adipocytes, in rat, 83
 inhibition by Q¹²¹PC-1, 831
 Q¹²¹PC-1 interactions, 831
 sensitization by TLK16998, 824
 signaling in type 2 diabetic patient relatives, 2572
 small-molecule sensitizers, 824
 Insulin receptor activators, small molecule, 2323
 Insulin receptor substrate-1 allelic variants in PCOS insulin resistance, 2164
 degradation of, trigger by phosphorylation, 24
 Gly972Arg polymorphism, and insulin secretion, 882
 tyrosine phosphorylation, in type 2 diabetic patient relatives, 2572
 Insulin receptor substrate-2, allelic variants in PCOS insulin resistance, 2164
 Insulin receptor substrate proteins and β -cell function, S140
 subcellular localization of, in mice, 1455
 Insulin receptor-deficiency, endocrine pancreas in, in mouse pups, S146
 Insulin resistance adiponectin levels in, in rhesus monkeys, 1126
 adipose tissue remodeling in, pioglitazone and, 1863
 amelioration by AJ-9677, in KK-A^y/Ta diabetic obese mouse, 113
 AMPK activation in, in rats, 1076
 apolipoprotein C1 protection against, in mice, 2779
 cardiomyocyte dysfunction with, in sucrose-fed rats, 1186
 cellular mechanism of, in nutritionally induced *P. obesus*, 584
 by ceramide, 2563
 dyslipidemia of, hepatic proteoglycans and, 2126
 endothelial, in type 2 diabetic patients with ischemic heart disease, 2611
 fatty acid uptake and metabolism in, in Zucker diabetic fatty rats, 1389
 fatty acid-induced, susceptibility to, in women, 1344
 free fatty acid-induced, prevention by thiazolidinedione, in male Wistar rats, 2316
 GH-induced, 1891
 free fatty acids and, 2301
 HDLs in, in apoA-II transgenic mice, 643
 high-fat diet-induced, in PPAR- α -null mice, 2809
 in high-salt diet-fed rats, 573
 hLPL overexpression and, in mouse skeletal muscle, 1064, 1512
 hyperglycemia-induced, insulin receptor dephosphorylation in, in rat adipocytes, 83
 indinavir and, 1397
 induction of by free fatty acids, in rats, 418
 by indinavir, 1378
 by neflavir, in 3T3-L1 adipocytes, 1425
 by overfeeding, 2786
 insulin-resistant sensitizers in, 2323
 intramyocellular lipid accumulation and, in rats, 123
 intramyocellular lipid and, 2337

α-lipoic acid protection against, in rat L6 muscle cells, 404
in liver IGF-I-knockout mice, 1110
muscle, fatty acids and, 1344
nonalcoholic fatty liver disease and, 1844
P20 and, 1821
PC-1 gene in, 1952
PET dose response in, in skeletal muscle, 2069
plasma FFAs and, 1612
in polycystic ovary syndrome, IRS-1 and IRS-2 allelic variants in, 2164
pubertal, 2444
rescue by transgenic leptin, in mouse model, 1440, 1675
resistance to exercise-induced glucose uptake in skeletal muscle with, in type 1 diabetes, 1371
skeletal muscle, impaired glucose transport and phosphorylation interactions in, 2069
Insulin sensitivity
antilipolytic, PPAR- γ 2 Pro12A1a and, 876
of endogenous glucose production suppression, 1449
and fat, in prepubertal children, 477
free fatty acid effects on, in PPAR- γ 2 Pro12A1a, 1143
gene effects on, in familial combined hyperlipidemia, 2396
intramyocellular lipid content and, 2579
oral glucose tolerance test minimal model index of, 150
p85 α variants and, 690
PPAR- α effects on, lipids and, in high fat-fed rats, 411
in RII $\beta^{-/-}$ mice, 2555
Insulin sensitization, thiazolidinedione mechanism of, 1083
Insulin therapy
short-term improvement of, effects on hepatic glycogen metabolism in type 1 diabetes, 392
for type 2 diabetic patients with ischemic heart disease, 2611
Insulin-like growth factor binding protein
IGFBP-1, phosphorylation in IGFBP-1 transgenic mice, 32
Insulin-like growth factor I
gene polymorphism, 637
inhibition of diabetic cardiomyopathy by, 1414
liver IGF-I-knockout mice, insulin resistance in, 1110
liver-derived, metabolic effects of, 1539
proliferation of keratinocytes by, insulin activation of PKC δ in, 255
signaling in diabetic retina by, 175
Insulin-like growth factor II
mannose-6-phosphate receptor, in diabetes-impaired nephrogenesis, 1069
Insulinoma-associated tyrosine phosphatase-like protein IA-2
coding and promoter regions, 2406
gene splicing, in pancreas and lymphoid organs, 895
preparation for detection of autoreactive T-cells, in type 1 diabetes, 1749
Insulonotropic polypeptide, glucose-dependent, postprandial levels, in type 2 diabetes, 609
Insulin-producing cells
AR42J cell differentiation into, neurogenin 3 in, S10
Fas regulation by cytokines in, 1741
proliferation of, inhibition by STAT5, S40
Insulin-resistant sensitizers, in insulin resistance, 2323
Insulin-secreting cells
free ADP in, 291
JNK activity in, 2721
Interferon- γ , signaling in β -cells, 2744
Interleukin-1 β -induced islet cell death, 551
Interleukin-1 β
-induced β -cell apoptosis, imidazoline protection against, S70
-induced protein expression changes in rat islets, proteome analysis of, 1056
JNK stimulation by, in insulin-secreting cells, 2721
1st International NOD Mouse T-cell Workshop report, 2459
Internet, online monitoring, of gene expression in β -cells, S15
Intramyocellular fat, plasma FFAs and, 1612
Intramyocellular lipids
and insulin resistance, 2337
in rats, 123
and insulin sensitivity, 2579
Intrauterine growth retardation, type 2 diabetes with, in rat, 2279
IPFL/PDX1 deficiency, and β -cell dysfunction, in *P. obesus*, 1799
IRS-2 gene, in late-onset type 2 diabetes, 1949
Ischemic heart disease, type 2 diabetes with, endothelial insulin resistance in, 2611
Islet amyloid polypeptide
human hIAPP-transgenic mice, oophorectomy promotion of islet amyloid formation in, S184
pro-IAPP processing in PC2-knockout mice, 534
Islet cell antigen 512 (ICA512). *see* Insulinoma-associated tyrosine phosphatase-like protein
Islet duodenal homeobox-1, and GLP-1 induction of β -cell differentiation, 784
Islet-specific glucose-6-phosphatase catalytic subunit-related protein gene promoter, mouse, *in situ* footprinting of, 502

J
Japanese subjects
maturity-onset diabetes in, *NEUROG3* mutations and, 694
with type 2 diabetes, Pax4 gene mutation in, 2864
JNK. *see* c-Jun NH₂-terminal kinase

K
Keratinocytes
glucose effects on, 1627
IGF-1-induced proliferation of, insulin activation of PKC δ in, 255
Kidney
fetal, diabetes-impaired, IGF-II/M6PR in, 1069
glucose handling
in humans, 747
in hypoglycemia, 2087
release, measurements of, 905
structure of, antihypertensive therapy effects on, in type 1 diabetic subjects with albuminuria, 843
Kidney-pancreas transplantation, effects on atherosclerotic risk factors, 496
Kinase insert domain-containing receptor, retinal expression of, induction by cyclic stretch and hypertension, 444
Kit, expression in β -cells and developing pancreas, 2021

KK-A^y/Ta diabetic obese mouse model, insulin resistance amelioration by AJ-9677 in, 113

L
L6 cells, glucose transport in, PED/PEA-15 effects on, mediation by PKC- α , 1244
L6 myotubes, troglitazone-induced GLUT4 translocation in, 1093
Lactate, release per fat cell, in type 2 diabetic relatives, 2344
Lactate monocarboxylate transporter, expression and distribution in islets, 361
Leptin
galanin interactions, 2666
and hepatic gene expression, in obese mice, 2268
mechanism of action, 733
plasma levels, and insulin secretion, 348
regulation of cholesterol metabolism by, 955
regulatory effects of, H₁-receptor disruption and, in mice, 385
transgenic rescue of lipoatrophic diabetes by, in mouse model, 1440, 1675
Leptin receptor, LEPR-B-expressing obesity/diabetes phenotype of LEPR-null mice, transgenic rescue of, 425
Leptin receptor deficiency, transgenic complementation of, 425
Leptin resistance
central histamine infusion in obese mice with, 377
induction by overfeeding, 2786
Lesions
atherosclerotic, smooth muscle accumulation in, in diabetic subjects, 851
glomerular, modulation by ACE inhibitors, in diabetic nephropathy, 2619
Leucine, regulation of β -cell mTOR-signaling pathway translation initiation by, 353
Linoleic acid, conjugated, antidiabetic properties of, 1149
Lipid transfer protein, activities in type 1 diabetes, 652
Lipids
intramyocellular and insulin resistance, 2337
in rats, 123
and insulin sensitivity, 2579
metabolism of
AICAR effects on, in rats, 1076
glucose and, 1402
G6Pase inhibition effects, 2591
liver-derived IGF-I and, 1539
regulation of, skeletal muscle lipolysis in, 1604
thiazolidinedione effects on, 1158
neutral, synthesis in β -cells, 315
peroxidation, inhibition of, wound healing stimulation by, in genetically diabetic mouse, 667
and PPAR- α effects on insulin sensitivity, in high fat-fed rats, 411
skeletal muscle and muscle fiber type, in type 2 diabetes and obesity, 817
single-fiber analysis of, 817
storage of, enhancement by AGAT- α overexpression, in adipose tissue and adipose tissue, 233
Lipoatrophic diabetes, rescue by transgenic leptin, in mouse model, 1440, 1675
Lipogenesis, G6Pase inhibition effects on, 2591
α-Lipoic acid

glucose uptake stimulation by, 1464
protective effects against insulin resistance, in rat L6 muscle cells, 404

Lipolysis
alterations in, subcellular localization of IRS family proteins and, in mice, 1455
basal, increase by nelfinavir, in 3T3-L1 adipocytes, 1425
 β -cell, GLP-1 and, 56
HSL δ gene polymorphism and, 2410
PPAR- γ_2 Pro12Ala and, 876
skeletal muscle, regulation of lipid oxidation by, 1604

Lipoprotein lipase
glycated LDL uptake mediation by, 1643
hyperinsulinemic clamp in transgenic mice, 2585
macrophage, regulation by fatty acids, 660
overexpression, insulin resistance and, in mouse skeletal muscle, 1064, 1512

Lipoproteins
high-density
 effects in adiposity and insulin resistance, in apoA-II transgenic mice, 643
 transcriptional regulation by glucose, 1850
low-density, glycated, cellular uptake mediation by lipoprotein lipase, 1643

Lipotoxicity
 β -cell, 315
 in obesity, S118
glucose, 2105

Liver
gene expression in, leptin and, in obese mice, 2268
glucokinase activity, in type 2 diabetes, 1351
glucose production by, insulin effects on, 1872
glycogen metabolism by
 stimulation by fructose, in humans, 1263
 in type 1 diabetes, 392
hypoglycemia in, detection of, 399
IGF-I derived from, metabolic effects of, 1539
insulin activity, in obese type 2 diabetes, 1363
Liver disease, nonalcoholic fatty, 1844
Liver IGF-I-knockout mice, insulin resistance in, 1110

Liver proteins, synthesis rates, insulin effects on, in swine model, 947

Liver proteoglycans
fatty acids and, 2126
insulin and, 2126

Low-density lipoprotein, glycated, cellular uptake mediation by lipoprotein lipase, 1643

Lymphocytes, autoaggressive, protection from, in transgenic mice, 2700

Lymphoid organs, IA-2 gene splicing in, 895

M

Macrophages
cholesterol ester metabolism in, regulation by insulin and leptin, 955
glycated LDL uptake in, mediation by lipoprotein lipase, 1643
lipoprotein lipase in, regulation by fatty acids, 660

Magnesium-sensitive protein phosphatase, acetyl-CoA carboxylase activation by, in β -cells, 1580

Magnetic resonance imaging, functional study of acute hypoglycemia effects on brain, 1618

Maternal diabetes, altered nephrogenesis due to, IGF-II/M6PR in, 1069

Matrix metalloproteinase 2
 effects in adipose differentiation, 2080
 production by adipocyte, 2080

Matrix metalloproteinase 9
 effects in adipose differentiation, 2080
 production by adipocyte, 2080

Maturity-onset diabetes, *NEUROG3* mutations and, in Japanese subjects, 694

Meal ingestion
 cephalic insulin response to, in humans, 1030
 initiation of, preprandial plasma ghrelin surges and, 1714

Melanocortins, mechanism of action, 733

Men
with type 1 diabetes, ^{18}F -FDG uptake at hypoglycemia in, 2329
type 2 diabetes risk among, drinking patterns and, 2390

Menopause, in type 1 diabetic women, 1857

Mesangial cells
hexosamines and fibronectin synthesis in, 2355
high glucose-enhanced ET-1 activation of ERK1/2 and α 1(IV) collagen in, 2376

Metabolic rate, cerulenin effects on, 733

Metabolic syndrome, nonalcoholic fatty liver disease in, 1844

Metabolism
and β -cell function and turnover, S84
and functional β -cell restoration after islet allotransplantation in type 1 diabetes, 277

Metallothionein, and streptozotocin diabetes, 2040

Microalbuminuria, onset in type 1 diabetes, 2842

Microencapsulated islets, survival in NOD mice, 1698

Microthromboses, in diabetic retinopathy, 1432

Microvascular dilation, coronary, in type 2 diabetes, 1180

MIN6 cells, tetracycline-inducible (Tet-On) gene expression in, S133

Minipig, β -cell mass decrease in, 2001

Mitochondria
protein synthesis, regulation by insulin, 2652
 $p70^{\text{S6K}}$ regulation, 353
superoxide overproduction by hyperglycemia, 1491

Mitogen-activated protein kinase
p38
 glucose uptake regulation by, 1464
 phosphorylation downstream of Bax-caspase-3, endothelial apoptosis and, 1472
 in RAGE-mediated NF- κ B activation, 1495
p44/p42, in RAGE-mediated NF- κ B activation, 1495

Mitogen-activated protein kinase α and β , p38, activation by insulin, and rat skeletal muscle contraction, 478

Molecular aspects
of pancreatic development, S5
regulation of Fas expression in β -cells, S83

Monocarboxylate transporter, expression and distribution in islets, 361

Monoclonal antibodies, hamster anti-murine CD154 mAb MRI, chronic, islet graft survival prolongation by, in NOD mice, 270

Monounsaturated fatty acids, effects on β -cell turnover and function, 69

Motor nerve conduction velocity, antioxidant treatment and, 1927

Mouse studies
apoA-II transgenic mice, 643
apolipoprotein C1 protection against obesity and insulin resistance, 2779
 β -cell mass in, in vivo measurement of, 2231
 β -cell-deficient mice, diabetogenic T cells in, 763
 β -cell-deficient NOD mice, diabetogenic T cells in, 763
C57BL/6J mice, diabetic embryopathy in, 1193
chromosome 18 association with autoimmunity, 184
clonal α cells, α Tc6 cells, exocytosis of l-glutamate by, 1012
db/db mice, GLUT4 overexpression effects in, 593
diabetic mice
phenotypic correction by adenoviral glucokinase expression, 2287
SREBP-1c and glucose homeostasis in, 2425
wound healing stimulation by inhibition of lipid peroxidation in, 667

GK gene locus transgenic mice, resistance to obesity-induced type 2 diabetes in, 622

HGF effects on islet function and transplantation outcome, 2752

hIAPP-transgenic mice, oophorectomy promotion of islet amyloid formation in, S184

HSL-deficient mice, insulin secretion in, 1970

IGFBP-1 transgenic mice, IGFBP-1 phosphorylation in, 32

IGRP gene promoter in situ footprinting, 502

Ins knockout mice, β -cell hyperplasia in, S150

insulin autoantibody induction by B9-23, 1274

insulin receptor-deficient pups, endocrine pancreas in, S146

IRS family proteins in, subcellular localization of, 1455

KK-A^y/Ta diabetic obese mouse model, insulin resistance amelioration by AJ-9677 in, 113

KK/Ta mouse model, susceptibility loci contributing to type 2 diabetes in, 1943

LEPR-null mice, LEPR-B-expressing obesity/diabetes phenotype of, transgenic rescue of, 425

leptin regulatory effects in, H₁-receptor disruption and, 385

leptin-resistant obese mice, central histamine infusion in, 377

lipoatrophic diabetes model, rescue by transgenic leptin, 1440, 1675

lipoprotein lipase-transgenic mice, hyperinsulinemic clamp in, 2585

liver IGF-I-knockout mice, insulin resistance in, 1110

MCKhLPL mice, insulin resistance in, 1064, 1512

NOD mice
autoantibodies in, 2451
diabetes in, decrease by adenovirus genes, 980

Idd10 and *Idd18* loci mapping by genetic interaction in, 2633

Idd5.1 mapping for autoimmune diabetes in, 2874

islet graft survival prolongation by CD40-CD154 blockade in, 270

microencapsulated islet survival in, 1698

NKT cell deficiency in, 2691

oral wound healing in, 2100

phogrin T-cell epitopes in, 1729

T-cell expansion in, 1992

T-cell Workshops report, 2459

NOD mice, β -cell-deficient, diabetogenic T cells in, 763

obese mice, leptin and hepatic gene expression in, 2268

PC2-knockout mice, pro-IAPP processing in, 534

PPAR- α -null mice, and high-fat diet, 2809

RII $\beta^{-/-}$ mice, insulin sensitivity in, 2555

transgenic mice
cell surface GLUT4 in, 593
protection from autoaggressive lymphocytes, 2700
reversible β -cell autoimmunity and hyperplasia in, 2260

SOD-1 protection against early diabetic glomerular injury in, 2114

MR1, chronic, islet graft survival prolongation by, in NOD mice, 270

Mucosal antigen, diabetogenic CTL priming by, 771

Muscle(s). *see also* Skeletal muscle; Smooth muscle
AMPK activation in, in type 2 diabetes, 921
gene expression in, nonesterified fatty acids and, in rats, 601
GFAT-1 expression in, selective, 2419
GLUT4 content, effects of oral creatine supplementation on, in humans, 18
glycogen synthesis in, regulation by glucose, glycogen, and insulin, in human cells, 720

insulin activity in, TNF- α effects on, in human cells, 1102

insulin capillary recruitment in, in hyperinsulinemia, 2682

insulin resistance in
fatty acid uptake and metabolism with, in Zucker diabetic fatty rats, 1389
fatty acids and, 1344
 α -lipoic acid protection against, in rat L6 cells, 404

insulin signaling in, in high fat-fed rats, 1901

lipids, and PPAR- α effects on insulin sensitivity, in high fat-fed rats, 411

triglyceride content, in lipoprotein-lipase transgenic mice, 2585

Muscle carnitine palmitoyltransferase-1, inhibition of, promotion of intramyocellular lipid accumulation and insulin resistance by, in rats, 123

Muscle fibers
slow, GLUT4 in, in type 2 diabetes, 1324
types of, skeletal muscle lipid content and oxidative enzyme activity and, in type 2 diabetes and obesity, 817

Muscle-protein breakdown, inhibition by growth hormone, 96

Mutations
 β -cell gene, pathophysiology of, S101
 β -cell transcription factors, S94

CART gene, in obese children, 2157

diabetes-associated *ACVR2B* mutations, in French patients, 1219

DRD2 gene Ser311Cys, and energy expenditure, 901

glucokinase, pathophysiology of, S101

HNF-1 α
aminoaciduria with, 2047
pathophysiology of, S101

missense Pax4 gene, in type 2 diabetes in Japanese, 2864

NEUROG3, and maturity-onset diabetes in Japanese subjects, 694

point *CTLA4* gene, in West African type 1 diabetes patients, 2169

sulfonylurea receptor, congenital hyperinsulinism due to, insulin dysregulation in, 322

Myoblasts, glycogen synthesis in, regulation by glucose, glycogen, and insulin, in human cells, 720

Myocardial infarction, risk for, IGF-I gene polymorphism and, 637

Myocytes, cell death, hyperglycemia and p53 and, 2363

Myofibrils, degeneration induction by glucose and palmitic acid, in rat cardiomyocytes, 2105

Myotubes, L6, troglitazone-induced GLUT4 translocation in, 1093

N

Na-Pi cotransporter, expression during AR42J cell differentiation, S39

Natural killer T-cell deficiency, in NOD mice, 2691

Necrosis, IL-1-induced, of islet cells, 551

Nelfinavir, adipocyte metabolism alteration by, 425

Neonates, GLP-1 treatment in, β -cell neogenesis by, in rats, 1562

Nephrogenesis, diabetes-impaired, IGF-II/M6PR in, 1069

Nephropathy, diabetic candidate gene screening in, 1214
glomerular lesions in, modulation by ACE inhibitors, 2619

Nerve growth factor, effects on insulin secretion and barium current, 1755

Nestin-positive stem cells, differentiation of, 521

Neural cell adhesion molecule, sialylated, S125

Neurogenin 3
in AR42J cell differentiation, S10
human *neurogenin3* promoter, 928, 1512, 1675

NEUROG3 mutations, and maturity-onset diabetes in Japanese subjects, 694

regulation of, 928, 1512, 1675

Neuropathy
autonomic, and parental diabetes, Fredericia Study, 630
diabetic, vascular dysfunction in, 1927

Neuropeptide Y
hypothalamic, ghrelin effects on, in rat, 2438
overexpression, and obesity, 1206
secretion of, modulation by galanin, 2666

Neuropeptide Y/Y1 receptor, hypothalamic pathway, activation by ghrelin, 227

Nicorandil
action on K_{ATP} channels, 2253
sulfonylurea interactions, 2253

Niddm1i gene locus, stimulus secretion coupling to, in GK rats, 2737

Nitric oxide
glucose uptake stimulation by, in rat skeletal muscle, 241

metabolism during cardiac surgery, diabetes and, 2603

Nitric oxide synthase, β -cell neuronal nNOS, insulin secretion regulation by, 1311, 2177

NN2211, weight loss therapy with, 2530

Nuclear factor- κ B
activation of
dsRNA-induced, in islets, 283

RAGE-mediated p38 MAPK-dependent, 1495
sustained, diabetes-associated, 2792

and β -cell apoptosis, 2219

and Fas regulation by cytokines, 1741

Nutrients, PPAR γ gene-nutrient interactions, 686

O

ob gene, effects on endocrine cell proliferation and differentiation in transplanted human islets, 301

Obesity
adipose tissue remodeling in, pioglitazone and, 1863

adrenoceptor gene variants and, in Caucasian women, 91

apolipoprotein C1 protection against, in mice, 2779

β -cell lipotoxicity in, S118

CART gene mutations in children with, 2157

central histamine infusion in leptin-resistant mice with, 377

chromosome 18p11 loci for type 2 diabetes with, genome scan for, 675, 1512

combined dyslipidemia in, normalization by ezetimibe, in hyperinsulinemic hamsters, 1330

endothelial dysfunction induction in, 159

gene expression profiling of omental fat in, 2822

ghrelin levels in, in humans, 707

ghrelin-induced, in rats, 2540

glucose metabolism in Zucker rats with, AICAR effects on, 1076

GLUT4 expression in, 1324

hepatic insulin activity in type 2 diabetes with, 1363

leptin and hepatic gene expression in, in mice, 2268

lipid metabolism in Zucker rats with, AICAR effects on, 1076

neuropeptide Y overexpression and, 1206

resistance to type 2 diabetes with, in GK gene locus transgenic mice, 622

resistin/Fizz3 expression and, 2199

skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in, 817

SUR1 sequence variants and, 697

Obesity/diabetes phenotype
LEPR-B-expressing, of LEPR-null mice, transgenic rescue of, 425

Oligonucleotide arrays, high-density, identification of novel cytokine-induced genes in β -cells by, 909

Omental fat, gene expression profiling of, 2822

Online monitoring, of gene expression in β -cells, S15

Oophorectomy, promotion of islet amyloid formation by, in hIAPP-transgenic mice, S184

Oral glucose tolerance test, 2-h criteria, type 1 diabetes by, 470

Oral glucose tolerance test minimal model analysis, of β -cell function and insulin sensitivity, 150

Oral wound healing, in NOD mice, 2100
 Orexin neurons, activation by hypoglycemia, 105
 Orexin-A, glucose-sensitive neuron excitement by, in rat hypothalamus, 2431
 Orexin-B, hypothalamic levels, increase by hypoglycemia, 105
 Osteopontin, stimulation by hypoxia, 1482
 Overfeeding, leptin and insulin resistance induction by, 2786
 Overstimulation, and β-cell function, S122
 Oxidative enzymes, skeletal muscle, and muscle fiber type, in type 2 diabetes and obesity, 817
 Oxidative stress
 AngII-mediated, inhibition by IGF-1 overexpression, 1414
 endothelial dysfunction induction by, in obesity, 159
 insulin resistance induced by, α-lipoic acid protection against, in rat L6 muscle cells, 404
 Oxygen tension, in transplanted rat islets, 489

P
 P20, and insulin resistance, 1821
 p38 mitogen-activated protein kinase glucose uptake regulation by, 1464 phosphorylation downstream of Bax-caspase-3, endothelial apoptosis and, 1472
 in RAGE-mediated NF-κB activation, 1495
 p38 mitogen-activated protein kinase α and β, activation by insulin, and rat skeletal muscle contraction, 478
 p44/p42 mitogen-activated protein kinase, in RAGE-mediated NF-κB activation, 1495
 p53, activation by hyperglycemia, 2363
 p53-related genes, activation by hyperglycemia, 2363
 p57^{KIP2}, expression in β-cells, 2763
 p70 S6 kinase, mitochondrial regulation of, 353
 p85α, variants, and insulin signaling *in vivo*, 691
 Palmitate
 glycogen inhibition by, 2210
 protein kinase B/Akt inhibition by, 2210
 Palmitic acid
 apoptosis modulation by, in rat cardiomyocytes, 2105
 myofibril degeneration induction by, in rat cardiomyocytes, 2105
 Pancreas
 development of biology of, S5
 Kit expression during, 2021
 embryonic cell expansion by EGF, 1571
 endocrine
 cell survival, ATP-sensitive K⁺ channels in, S48
 differentiation of ATP-sensitive K⁺ channels in, S48
 in pig-to-mouse model, 962
 fetal, ontogeny of, 962
 in insulin receptor-deficient mouse pups, S146
 nestin-positive stem cell differentiation into, from adult islets, 521
 plasticity of, S30
 exocrine
 monocarboxylate transporter expression and distribution in, 361
 nestin-positive stem cell differentiation into, from adult islets, 521

PDX-1 misexpression in, glucose tolerance and acinar dysmorphogenesis by, 1553
 Iα-2 gene splicing in, 895
 insulin secretory response, rosiglitazone effects on, 2598
 precursor cells, novel line for β-cell differentiation study, S42
 response to mild hypoglycemia, 2487
 Pancreas transplantation. *see also* Kidney-pancreas transplantation
 insulin delivery in, systemic versus portal effects on insulin action and VLDL metabolism, 1402
 Pancreatectomy, for chronic pancreatitis, prevention of diabetes by autoislet transplantation after, 47
 Pancreatic β-cells. *see also* β-cells
 Pancreatic biopsy, in type 1 diabetes, 1269
 Pancreatic duodenal homeobox-1 gene expression
 β-cell-specific, S131
 glucose tolerance and acinar dysmorphogenesis by, in exocrine pancreas, 1553
 regulatory elements in, S37
 shutting in β-cells, 2244
 Pancreatic duodenal homeobox-1 deficiency and β-cell dysfunction, in *P. obesus*, 1799 and glucose-regulated insulin gene expression, in *P. obesus* type 2 diabetes, S138
 Pancreatic islet cells. *see also* β-cells
 adeno-associated virus transduction of, 515
 adrenylyl cyclase activity in, in rat, 2505
 allogeneic, stable, reversal of streptozotocin-induced diabetes with, in type 1 model, 1227
 allorejection of, protection against, by barium-alginate membrane, 1698
 allotransplantation in type 1 diabetes, 277
 amyloidosis of characteristics of, 2514
 promotion by oophorectomy, in hIAPP-transgenic mice, S184
 antibodies, GAD65 autoantibodies in relatives with, 1735
 apoptosis in, induction by high glucose, in human cells, 1290
 clusters, cytoplasmic Ca²⁺ in, measurements of, 540
 congenic, phenotyping of, in GK rats, 2737
 cytotoxic damage to, prevention by TIMP-1, 1047
 death of, IL-1-induced, 551
 development of, HNF-1α and, 2472
 differentiation of, ATP-sensitive K⁺ channels in, S48
 dsRNA-induced activation of NF-κB in, 283
 Fas receptor upregulation by glucose in, 1683
 free fatty acid cytotoxicity in, 1771
 function of HGF effects on, in mice, 2752
 pituitary adenylate cyclase-activating peptide and, 1959
 gene expression in, in suckling rats, 2053
 glucose induction of hormone-sensitive lipase in, in rat islets, 2225
 glucose metabolism and pulsatile insulin release from, 1785
 glycerol-stimulated proinsulin biosynthesis in, rat, 1791
 IL-1β-induced protein expression changes in, proteome analysis of, in rats, 1056
 IL-1-induced necrosis and apoptosis of, 551
 insulin release in
 in GK rat, S108
 stimulation by human anti-CD38 autoantibodies, 985
 metabolism of, HNF-1α and, 2472
 microencapsulated, survival in NOD mice, 1698
 monocarboxylate transporter expression and distribution in, 361
 nestin-positive stem cells from, differentiation of, 521
 p57^{KIP2} expression in, 2763
 plasticity of, S30
 pulsatile insulin release from, glucose metabolism and, 1785
 pyruvate dehydrogenase kinase isoform expression in, in rat, 2729
 stimulus-secretion coupling in, in *P. obesus*, 308
 total mass, 1763
 transduction with fusion proteins, 1706
 transplantation
 autoantibody response to, in type 1 diabetes, 2464
 endocrine cell proliferation and differentiation in, 301
 HGF effects on, in mice, 2752
 outcomes and insulin secretion after, 710
 oxygen tension in, rat, 489
 in type 1 diabetes, 277
 triacylglycerol content, hyperglycemia and, in Zucker diabetic fatty rats, 2481
 triglyceride content, free fatty acid cytotoxicity and, 1771
 in type 2 diabetes, S1
 volume, volume-weighted mean, 1763
 Pancreatic islet grafts
 function of, heme oxygenase-1 induction and, 1983
 survival prolongation by CD40-CD154 blockade, in NOD mice, 270
 Pancreatitis, chronic, pancreatectomy for, prevention of diabetes by autoislet transplantation after, 47
 Parental diabetes, autonomic neuropathy and, Fredericia Study, 630
 Parent-of-origin effects, genome-wide scan for, 2850
 Pax4 gene, missense mutation in type 2 diabetes in Japanese, 2864
 PC-1
 in insulin resistance, 1952
 Q allele variant (GLN¹²¹) Q¹²¹PC-1, insulin receptor interactions and inhibition by, 831
 PC2. *see* Prohormone convertase enzyme 2
 PDX-1. *see* Pancreatic duodenal homeobox-1
 PED/PEA-15, glucose transport effects, mediation by PKC-α, in L6 skeletal muscle cells, 1244
 Peripheral tissue insulin resistance, fatty acid-induced, susceptibility to, in women, 1344
 Peroxisome proliferator-activated receptor(s), in macrophage LPL regulation by fatty acids, 660
 Peroxisome proliferator-activated receptor-α and high-fat diet, 2809
 and insulin sensitivity, in high fat-fed rats, 411
 Peroxisome proliferator-activated receptor-γ, activity, resistin/Fizz3 expression and, 2199
 Peroxisome proliferator-activated receptor-γ2 gene, and weight loss, 2172

Peroxisome proliferator-activated receptor- χ ligands, and adiponectin expression, 2094

Peroxisome proliferator-activated receptor- γ Ala¹² variant, association with diabetes resistance, 891

gene-nutrient interactions, 686

Peroxisome proliferator-activated receptor- γ_2 , Pro12A1a variant association with type 2 diabetes and trait differences, 886

free fatty acid effects on insulin secretion and sensitivity in, 1143

and lipolysis, 876

Phenotype

- of congenic islets, in GK rats, 2737
- correction of diabetes by, in mice, 2287
- of rebred Cohen diabetic rat, 2521

Phogrin T-cell epitopes, in NOD mice, 1729

Phosphatidylinositol 3-kinase activity, subcellular localization of IRS family proteins and, in mice, 1455

rosiglitazone effects on pancreatic insulin secretory response and, 2598

Phosphoenolpyruvate carboxykinase, gene expression reduction by GSK-3 inhibitors, 937

Phosphoinositide 3-kinase, p85 α subunit, variants, and insulin signaling in vivo, 691

Phosphoprotein P20, and insulin resistance, 1821

Phosphorylation

- IGFBP-1, in IGFBP-1 transgenic mice, 32
- impaired glucose transport interactions, in insulin resistance, 2069
- serine/threonine, IRS-1 degradation trigger by, 24

Pigment epithelium-derived factor, loss in angiogenic eye disease, 2641

Pigs. *see* Swine studies

Pima Indians

- gamma globulin levels and type 2 diabetes in, 1598
- genome-wide scan for parent-of-origin effects in, 2850
- insulin secretion in, 1828

Pioglitazone

- and adipose tissue remodeling, 1863
- insulin-sensitizing mechanism of, 1083

Pituitary adenylate cyclase-activating peptide, and islet function, 1959

Plasma adiponectin, PPAR χ ligands and, 2094

Plasma apolipoprotein B-48 lipoproteins, modulation by hyperinsulinism, 462

Plasma free fatty acids

- effects on intramyocellular fat content, 1612
- in subjects at high-risk for type 2 diabetes, 2548

Plasma ghrelin, preprandial surges in, 1714

Plasma glucose

- α -cell responses to, in dog, 367
- β -cell responses to, in dog, 367
- decrease by tramadol, in diabetic rats, 2815

Plasma 8-hydroxyguanine, in diabetic rat, 2837

Plasma leptin, and insulin secretion, 348

Plasma membrane glycation, endothelial, in diabetes, 1666

Plasmalemma-associated proteins, endothelial, in diabetes, 1666

Plasminogen activator inhibitor type 1, insulin-mediated signal transduction, in HepG2, 1522

Plasticity

- endocrine pancreas, S30
- islet, S30

Platelets, induction by hyperglycemia, 1491

Polycystic ovary syndrome, insulin resistance in, IRS-1 and IRS-2 allelic variants in, 2164

Polymorphic studies, in diabetes, 2646

Polyreactive type 1 diabetes, Fas function in, 483

Portal vein glucosensor locus, confirmation of, 399

insulin delivery, effects on insulin action and VLDL metabolism, 1402

Positron emission tomography dose response in insulin-resistant skeletal muscle, 2069

FDG-PET, in counter-regulatory failure, 2329

Potassium channels, ATP-sensitive activation by insulin, in β -cells, 2192

in endocrine pancreas cell survival and differentiation, S48

nicorandil action on, 2253

Preadipocytes, differentiational inhibition by indinavir, 1378

Pro12Ala gene, and weight loss, 2172

Prohormone convertase enzyme 2, in mice pro-IAPP processing, 534

Proinsulin

- glycerol-stimulated biosynthesis, in rat islets, 1791
- preparation for detection of autoreactive T-cells, in type 1 diabetes, 1749

Pro-islet amyloid polypeptide, processing in PC2-knockout mice, 534

Prolactin, insulin-producing cell proliferation induced by, inhibition by STAT5, S40

Protein

- metabolism in cystic fibrosis, 1336
- mitochondrial and cytoplasmic synthesis of, regulation by insulin, 2652
- muscle-protein breakdown inhibition by growth hormone, 96
- retaining effects of growth hormone during fasting, 96

Protein kinase, dsRNA-dependent, and dsRNA-induced activation of NF- κ B in islets, 283

Protein kinase A, RII $\beta^{-/-}$ mice, insulin sensitivity in, 2555

Protein kinase B, inhibition by p85 α variants, 691

Protein kinase B/Akt, inhibition by palmitate, 2210

Protein kinase C

- angiotensin II-dependent translocation, 1918
- in high glucose-enhanced ET-1 activation of ERK1/2 and α 1(IV) collagen, in mesangial cells, 2376

Protein kinase C- α , PKC- ζ inhibition by, in L6 skeletal muscle cells, 1244

Protein kinase C- δ , activation by insulin, in proliferation, 255

Protein kinase C- ϵ , overexpression in skeletal muscle, before diabetes, 584

Protein kinase C- ζ and GLP-1-induced β -cell growth, 2237

inhibition by PKC- α , in L6 skeletal muscle cells, 1244

Protein phosphatase, glutamate- and magnesium-sensitive, acetyl-CoA carboxylase activation by, in β -cells, 1580

Proteoglycans, hepatic

- fatty acids and, 2126
- insulin and, 2126

Proteome analysis, of IL-1 β -induced protein expression changes in rat islets, 1056

Psammomys obesus

- β -cell dysfunction in, 1799

β -cell glucotoxicity in, S113

islet stimulus-secretion coupling in, 308

nutritionally induced insulin resistance in, cellular mechanism of, 584

PDX-1 deficiency in

- β -cell dysfunction and, 1799
- glucose-regulated insulin gene expression and, S138

Pubertal insulin resistance, 2444

Pyruvate dehydrogenase kinase, isoform expression in islets, in rat, 2729

Q

QTc dispersion, and diurnal BP variations, in diabetes, 837

Québec Family Study, genome-wide scan for abdominal fat in, 614

R

Rab3A, association with calmodulin, 2029

RAGE. *see* Receptor for advanced glycation end-products

Rapamycin, mammalian target mTOR of, β -cell translation initiation through, regulation by leucine, 353

Rat studies. *see also Psammomys obesus*

- BB rat thymocytes, 972, 2414
- β -cell apoptosis in, Bcl-2 and Bax- Ω downregulation and, S82
- blastocyst Bcl-2, 143
- cardiomyocyte apoptosis modulation by glucose and palmitic acid, 2105
- chromosome 18 association with autoimmunity, 184
- chronic AICAR effects on skeletal muscle insulin-stimulated glucose uptake and GLUT4 translocation, 12
- diabetic rats
- cardiac β -adrenoceptor expression in, 455
- cardiac insulin signaling in, 2709
- combination benzylamine and vanadate treatment of, 2061
- plasma 8-hydroxyguanine levels in, 2837
- tramadol plasma glucose-lowering effects in, 2815
- exercise training and insulin action, 2659
- exercise-stimulated glucose turnover, glucosamine and, 139
- ghrelin effects on hypothalamus, 2438
- ghrelin-induced hyperphagia and obesity in, 2540

GK rats

- β -cell development in, S84
- β -cell function and viability in, S89
- insulin release in islets in, S108
- phenotyping of congenic islets in, 2737
- gluconeogenesis in small intestine, 740
- glucose induction of hormone-sensitive lipase in islets, 2225
- glucose uptake in skeletal muscle, NO-stimulated, 241
- GLUT4 translocation by troglitazone in, in adipocytes, 2296
- glycerol-stimulated proinsulin biosynthesis in islets, 1791

high fat-fed rats

- insulin signaling in muscle in, 1901
- lipids and PPAR- α effects on insulin sensitivity in, 411

high free fatty acid availability in, energy fuel channeling toward fat vs muscle during, 601

high-salt diet-fed rats, insulin resistance in, 573

hypertensive rats, muscle glucose transport in, 2148

hypoglycemia effects on adrenal sympathetic activity, 1119

insulin p38 MAPK α and β activation and skeletal muscle, 478

insulin receptor dephosphorylation in adipocytes, 83

insulin resistance induction by free fatty acids, 418

insulin-resistant L6 muscle cells, α -lipoic acid protection against, 404

insulin-resistant rats

- AMPK activation in, 1076
- intramyocellular lipid accumulation and, 123
- male Wistar rats, thiazolidinedione prevention of FFA-induced insulin resistance in, 2316
- myofibril degeneration by glucose and palmitic acid cardiomyocytes, 2105
- newborn rats, β -cell neogenesis by GLP-1 treatment in, 1562
- nonesterified fatty acids and gene expression in fat and muscle, 601
- orexin A excitement of GSN in, 2431
- pancreatic islets

 - adenylyl cyclase activity in, 2505
 - IL-1 β -induced protein expression changes in, proteome analysis of, 1056
 - pyruvate dehydrogenase kinase isoform expression in, 2729
 - transplanted, oxygen tension in, 489

- rebred Cohen diabetic rat, phenotype of, 2521
- suckling rats, islet gene expression in, 2053
- sucrose-fed rats, cardiomyocyte dysfunction with insulin resistance in, 1186
- thiazolidinedione action in skeletal muscle, 2309
- type 2 diabetic rats, intrauterine growth retardation and, 2279
- Zucker diabetic fatty rats

 - AICAR effects on glucose and lipid metabolism in, 1076
 - β -cell mass dynamics in, 1021
 - β -cell transcription defect in, 63
 - fatty acid uptake and metabolism in insulin-resistant muscle of, 1389
 - GIP receptor expression in, 1004
 - hyperglycemia and increased islet TAG content, 2481
 - tungstate effects in, 131

Receptor for advanced glycation end-products

- chromosome 6 vs chromosome 3 5'
- regulatory region variation, 2646

functional gene promoter polymorphisms, 1505

p38 MAPK-dependent NF- κ B activation mediated by, 1495

Relatives. *see* Families

Research, ADA-funded, year 2 status, 1222

Resistin/Fizz3, expression in humans, 2199

Retina

- angiopoietin-2 induction by All in, in bovine endothelial cells, 867
- metabolism in diabetes and galactosemia, 1938
- VEGF-R2 expression induction by cyclic stretch and hypertension, 444

Retinopathy, diabetic

- antioxidant effects on, 1938
- functional RAGE promoter polymorphisms and, 1505

IGF-I signaling in, 175

inhibition by aminoguanidine and aspirin, 1636

microthromboses in, 1432

Rhesus monkeys, insulin-resistant, adiponectin levels in, 1126

RNA, double-stranded, NF- κ B activation in islets by, 283

Rosiglitazone

- effects on β -cell mass dynamics in Zucker diabetic fatty rats, 1021
- effects on pancreatic insulin secretory response, 2598

S

Salt, insulin resistance in high-salt diet-fed rats, 573

Sand rat. *see* *Psammomys obesus*

Sarcoplasmic reticulum dysfunction, in diabetic heart, 2133

Saturated fatty acids, effects on β -cell turnover and function, 69

Sciatic nerve, epineurial arterioles, antioxidant treatment and, 1927

Second International Immunology of Diabetes Society Workshop for Standardization of T-cell Assays in Type 1 Diabetes, phase II report, 1749

Semicarbazide-sensitive amine oxidase substrates, antidiabetic effects in diabetic rats, 2061

Serine/threonine phosphorylation, IRS-1 degradation trigger by, 24

Serum, from type 1 diabetes patients, effects on cerebellar granule cells, S77

Sex differences, diet-induced type 2 diabetes with, rebred Cohen rat model of, 2521

Sex ratio, fetal, in C57BL/6J mice, 1193

Siblings. *see also* Families

- of type 1 diabetic children, autoantibody seroconversions in, 2625

Signal transducers and activators of transcription STAT5, inhibition of insulin-producing cell proliferation by, S40

Single nucleotide polymorphisms (SNPs)

- CAPN10 UCSNP-43, and insulin secretion, 2161
- of PC-1 gene, in insulin resistance, 1952

Skeletal muscle

- AGAT- α overexpression effects in, 233
- contraction of, insulin p38 MAPK α and β activation and, in rat, 478
- glucose transport in

 - in hypertensive rats, 2148
 - inhibition by indinavir, 1397
 - PED/PEA-15 effects on, mediation by PKC- α , in L6 cells, 1244

- glucose uptake in

 - insulin-stimulated, chronic AICAR treatment and, in rat, 12
 - NO-stimulated, in rat, 241

- glycogen synthase content, *GYS1 XbaI* gene polymorphism and, 195
- glycogen synthase kinase-3 regulation in, 265
- hexokinase isozymes in, in humans, 1253
- hLPL overexpression in, insulin resistance and, in mouse, 1064, 1512
- insulin activity in

 - with conjugated linoleic acid, 1149
 - gene expression regulation, 1134
 - glucose uptake and GLUT4 translocation stimulation, chronic AICAR treatment and, in rat, 12

- insulin resistance in, intramyocellular lipid and, 2337
- insulin signaling in

in glucose-intolerant relatives with type 2 diabetes, 2770

in high fat-fed rats, 1901

insulin-resistant

- impaired glucose transport and phosphorylation interactions in, 2069
- PET dose response in, 2069
- resistance to exercise-induced glucose uptake, in type 1 diabetes, 1371
- lipid content, in type 2 diabetes and obesity, 817
- lipolysis, regulation of lipid oxidation by, 1604
- oxidative enzyme activity, in type 2 diabetes and obesity, 817
- PKC ϵ overexpression in, before diabetes, 584
- single-fiber analysis of lipid and oxidative enzymes, 817
- thiazolidinedione action in, in rat, 2309
- UCP3 content, in type 2 diabetes, 2870

Skin keratinocytes

- glucose effects on, 1627
- IGF-1-induced proliferation of, insulin activation of PKC δ in, 255

Slow muscle fibers, GLUT4 in, in type 2 diabetes, 1324

Small intestine, gluconeogenesis in, in rat, 740

Small-molecule insulin receptor sensitizers, 824

Smoking, cigarette, and microalbuminuria onset in type 1 diabetes, 2842

Smooth muscle

- accumulation in atherosclerotic lesions, with diabetes, 851
- vascular smooth muscle cells

 - apoptosis of, glucose metabolism association, 1171
 - proliferation of, stimulation by hypoxia, 1482

SOD. *see* Superoxide dismutase

Sodium (Na)-Pi cotransporter, expression during AR42J cell differentiation, S39

Splanchnic uptake, of glucose free fatty acid effects on, in men, 727

- GLP-1 effects on, in type 1 diabetes, 565
- in type 2 diabetes, 1351

Splotch mice, diabetic embryopathy in, 1193

SREBP-1. *see* Sterol regulatory element-binding protein-1

Steatosis, hepatic, G6Pase inhibition and, 2591

Stem cells

- embryonic, insulin production by, 1691
- nestin-positive, differentiation of, 521

Sterol regulatory element-binding protein-1, intranuclear localization, impairment by indinavir, 1378

Sterol regulatory element-binding protein-1c, and glucose homeostasis, in diabetic mice, 2425

Streptozotocin-induced diabetes combination benzylamine and vanadate treatment of, in rats, 2061

plasma 8-hydroxyguanine levels in, in rats, 2837

reduction by metallothionein, 2040

reversal with stable allogeneic islet function, in type 1 model, 1227

Stress, oxidative

- AngII-mediated, inhibition by IGF-1 overexpression, 1414
- endothelial dysfunction induction by, in obesity, 159

Stretch-induced retinal VEGF-R2 expression, 444

Stromal cell-derived factor-1, gene variant, and type 1 diabetes, 1211

Sucrose
cardiomyocyte dysfunction with insulin resistance in rats fed, 1186

neuropeptide Y overexpression and obesity after high-sucrose feeding, 1206

Sudomotor responses, in sympathetic dysfunction in type 1 diabetes, 436

Sulfonylurea
nicorandil interactions, 2253
and pulsatile insulin secretion, in type 2 diabetes, 1778

Sulfonylurea receptor, mutations, insulin dysregulation in congenital hyperinsulinism due to, 322

Sulfonylurea receptor 1, SUR1 sequence variants, glucose metabolism and, 697

Superoxide, mitochondrial overproduction by hyperglycemia, 1491

Superoxide dismutase, Cu²⁺/Zn²⁺, protection against early diabetic glomerular injury in transgenic mice by, 2114

Suppressor of cytokine signaling-1, and IFN- γ signaling in β -cells, 2744

Suprachiasmatic nucleus, in daily glucose tolerance rhythms, 1237

Surgery, cardiac, nitric oxide metabolism during, diabetes and, 2603

Swine studies
diabetes-induced accelerated atherosclerosis, 1654

dipeptidyl peptidase IV inhibition and glucose-dependent insulinotropic peptide, 1588

insulin effects on liver protein synthesis rates, 947

Sympathetic injury, sudomotor responses in, 436

Sympathetic neural activity, adrenal, effects of hypoglycemia on, in rats, 1119

Systemic insulin delivery, effects on insulin action and VLDL metabolism, 1402

T

T-cells
autoantigens for workshops, 1749
auto-reactive, detection in type 1 diabetes, 1749

cytotoxic. *see* Cytotoxic T-lymphocytes

diabetogenic, in β -cell-deficient mice, 763

epitopes, phgrin, in NOD mice, 1729

expansion in type 1 diabetes, 1992

natural killer T-cell deficiency, in NOD mice, 2691

NOD Mouse T-cell Workshop report, 2459

Tetracycline-inducible (Tet-On) gene expression, in MIN6 cells, S133

Thiazolidinediones
insulin-sensitizing mechanism of, 1083
and lipid metabolism, 1158

PPAR γ -independent action in rat skeletal muscle, 2309

prevention of FFA-induced insulin resistance by, in male Wistar rats, 2316

Thymic organ cultures, BB rat adult, 972, 2414

Thymic tolerance, acquired, indirect allorecognition in, 1546

Tissue inhibitor of metalloproteinase-1, prevention of cytotoxic islet damage by, 1047

3T3-L1 adipocytes
metabolism of, neflifavir effects on, 1425

VEGF mRNA levels, troglitazone treatment effects on, 1166

TLK16998, insulin receptor sensitization by, 824

Toxicity
cytotoxicity
of free fatty acids, in islet cells, 1771
islet, prevention by TIMP-1, 1047

glucotoxicity, β -cell, in *P. obesus* type 2 diabetes, S113

lipotoxicity
 β -cell, 315
in obesity, S118

glucose, 2105

Training, exercise, and insulin action, in rat, 2659

Trait differences, PPAR- γ 2 Pro12A1a variant and, 886

Tramadol, plasma glucose-lowering effects in diabetic rats, 2815

Transcription factors
 β -cell, mutations, S94
expression in AR42J cell differentiation, S10

Transplantation
autoislet
long-term, 47
prevention of diabetes by, after pancreatectomy for chronic pancreatitis, 47

fetal endocrine pancreas, differentiation after, in pig-to-mouse model, 962

islet
autoantibody response to, in type 1 diabetes, 2464

endocrine cell proliferation and differentiation in, 301

HGF effects on, in mice, 2752

outcomes and insulin secretion after, 710

oxygen tension in, rat, 489

kidney-pancreas, effects on atherosclerotic risk factors, 496

pancreas, insulin delivery in, systemic versus portal effects on insulin action and VLDL metabolism, 1402

Triacylglycerol, islet cell content, increased, hyperglycemia and, in Zucker diabetic fatty rats, 2481

Tribute, to Bruce R. Zimmerman, 2883

Triglycerides
cellular accumulation of, free fatty acid cytotoxicity and, 1771

muscle content, in lipoprotein lipase-transgenic mice, 2585

Troglitazone
effects on plasma VEGF, 1166

GLUT4 translocation by, 1093
in rat adipocytes, 2296

Tropomodulin I, phosphorylation of, angiotensin II and, 1918

Tumor necrosis factor- α , effects on insulin action, in human muscle, 1102

Tungstate, effects in Zucker diabetic fatty rats, 131

Type 1 diabetes
with albuminuria, antihypertensive therapy effects on renal structure in, 843

animal models, international workshop on lessons from, 2451

anti-CD38 autoantibodies in Caucasians with, 752

atherosclerotic risk factors and endothelial function in, kidney-pancreas transplantation effects on, 496

autoaggressive lymphocytes in, protection from, in transgenic mice, 2700

autoreactive T-cells in, detection of, 1749

β -cell apoptosis in, S64

discovery of, 217

early onset of, *SDT* gene variant and, 1211

exercise-induced glucose uptake in, resistance to, in insulin-resistant skeletal muscle, 1371

¹⁸F-FDG uptake at hypoglycemia in, in men, 2329

GAD65 autoantibodies from, human recombinant, 1976

gene and cell-replacement therapy for, 2181

GLP-1 effects in, 565

HbA_{1c} levels in, genetic determination of, 2858

hepatic glycogen metabolism in, 392

HLA-DPB1 and, 1200

IA-2 autoantigen, autoimmunity against, by IA-2 gene splicing in pancreas and lymphoid organs, 895

Idd18 and *Idd18* loci for, mapping by genetic interaction, in NOD mice, 2633

insulin-resistant skeletal muscle in, resistance to exercise-induced glucose uptake in, 1371

islet allotransplantation in, 277

islet transplantation in, autoantibody response to, 2464

lipid transfer protein activities in, 652

menopause in women with, 1857

microalbuminuria onset in, 2842

nephropathy in, candidate gene screening with, 1214

oral wound healing in, in NOD mice, 2100

pancreatic biopsy in, 1269

polyreactive, Fas function in, 483

QTc dispersion and diurnal BP variations in, 837

renal glucose handling in hypoglycemia in, 2087

serum, effects on cerebellar granule cells, S77

siblings of children with, autoantibody seroconversions in, 2625

streptozotocin-induced, reversal with stable allogeneic islet function, 1227

sympathetic dysfunction in, sudomotor responses in, 436

T-cell expansion in, 1992

by 2-h OGTT criteria, 470

West African patients, *CTLA4* point mutation in, 2169

Type 2 diabetes
ACVR2B mutations associated with, in French patients, 1219

AMPK activation in, 921

Anexin I gene in, 2402

anti-CD38 autoantibodies in Caucasians with, 752

Av39NGKRP treatment of, 1813

β -cell development in, in GK rat model, S84

β -cell dysfunction in, S160, S169

PDX1 deficiency and, in *P. obesus*, 1799

β -cell function in, S140
abnormal, evidence for, S172
in GK rat model, S89

β -cell glucotoxicity in, in *P. obesus* model, S113

β -cell mass in, S140
expansion of, S189
preservation of, S188
reduction of, S169

β -cell neogenesis in, S186

β -cell number in, S169

β -cell viability in, in GK rat model, S89

chromosome 12q15 locus for, 204

chromosome 18p11 loci for, genome scan for, 675, 1512

in Ashkenazi Jews, 681

coronary microvascular dilation in, 1180
diet-induced, rebred Cohen rat model of, 2521
early onset, insulin secretion in adult offspring of patients with, 1828
familial aggregation of coronary artery calcium in families with, 861
gamma globulin levels and, in Pima Indian population, 1598
gene expression regulation by insulin in, in human skeletal muscle and adipose tissue, 1134
GK rat model of
 β -cell development in, S84
 β -cell function and viability in, S89
 insulin release in islets in, S108
GLP-1 and pulsatile insulin secretion in, 776
gluconeogenesis in, free fatty acid effects on, 810
glucose-intolerant relatives with, skeletal muscle insulin signaling in, 2770
glucose-regulated insulin gene expression and PDX-1 deficiency in, in *P. obesus* model, S138
GLUT4 expression in, 1324
GSK-3 inhibitors and, 937
hepatic glucokinase activity in, 1351
hepatic insulin activity in, 1363
high-risk subjects, free fatty acid uptake and oxidation in, 2548
hyperinsulinemia and gluconeogenesis in, 1807
insulin secretion in, S169
 impaired, PPAR- γ Ala¹² variant and, 891
 pulsatile, sulfonylurea and, 1778
after intrauterine growth retardation, in rat, 2279
with ischemic heart disease, endothelial insulin resistance in, 2611
islet stimulus-secretion coupling in, in *P. obesus* model, 308
islets in, S1
KK/Ta mouse model, susceptibility loci, 1943
late-onset, *IRs-2* gene in, in Finnish and Chinese subjects, 1949
obese patients with, gene expression profiling of omental fat in, 2822
obesity-induced, resistance to, in GK gene locus transgenic mice, 622
P. obesus model of
 β -cell glucotoxicity in, S113
 glucose-regulated insulin gene expression and PDX-1 deficiency in, S138
 islet stimulus-secretion coupling in, 308

p85 α variants and, 690
parent-of-origin effects in, genome-wide scan for, 2850
Pax4 gene mutation in, in Japanese, 2864
PDX1 deficiency and β -cell dysfunction in, in *P. obesus*, 1799
postprandial GIP and GLP-1 levels in, 609
PPAR- γ_2 Pro12A1a variant and, 886
prevention by increased glucokinase, 622
relatives
 GIP insulinotropic effects in, 2497
 insulin receptor signaling in, 2572
 lactate release per fat cell in, 2344
risk for
 drinking patterns and, among men, 2390
 IGF-I gene polymorphism and, 637
skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in, 817
splanchnic glucose uptake in, 1351
susceptibility loci contributing to, in KK/Ta mouse model, 1943
UCP3 content in, 2870
Tyrosine phosphatase IA-2, preparation for detection of autoreactive T-cells, in type 1 diabetes, 1749

U

Uncoupling protein
 regulatory effects of leptin on, H₁-receptor disruption and, in mice, 385
upregulation by central histamine infusion, in leptin-resistant obese mice, 377
Uncoupling protein 2
 free fatty acids and, in insulin secretion, 803
 gene expression, with conjugated linoleic acid, 1149
 overexpression in β -cells, 1302
Uncoupling protein 3, skeletal muscle content, in type 2 diabetes, 2870
Uremia, atherosclerotic risk factors and endothelial function in, kidney-pancreas transplantation effects on, 496

V

Vagal cooling, effects on low-dose insulin-induced hypoglycemia response, in dog, 558
Vanadate, low dosage, combined with benzylamine, in STZ-induced diabetic rats, 2061
Vascular dysfunction, in diabetic neuropathy, 1927
Vascular endothelial growth factor

expression of
 restoration by inhibition of lipid peroxidation, in genetically diabetic mouse, 667
retinal, induction by cyclic stretch and hypertension, 444
troglitazone treatment effects on, 1166
Vascular endothelial growth factor-receptor 2, retinal induction by cyclic stretch and hypertension, 444
Vascular smooth muscle cells
 apoptosis of, glucose metabolism association, 1171
proliferation stimulation by hypoxia, 1482
Vasodilation, coronary, in type 2 diabetes, 1180
Vasorelaxation, by CO, in diabetes, 166
Ventromedial hypothalamic nucleus, glucosensing neurons in, 2673
Very low-density lipoprotein, metabolism of, systemic versus portal insulin delivery effects on, in pancreas transplantation, 1402
Vitamin C, protective effects against endothelial dysfunction in obesity, 159

W

Weight, birth, diabetes-associated HLA-DQ genes and, 2879
Weight loss, PPAR- γ 2 gene and, 2172
Weight loss therapy, with NN2211, 2530
West African type 1 diabetes patients, *CTLA4* point mutation in, 2169
Women
 Caucasian, adrenoceptor gene variants and obesity in, 91
 susceptibility to fatty acid-induced peripheral tissue insulin resistance, 1344
 type 1 diabetic, menopause in, 1857
Wound healing
 oral, in NOD mice, 2100
stimulation by inhibition of lipid peroxidation, in genetically diabetic mouse, 667

Z

Zimmerman, Bruce R., tribute to, 2883
Zinc, Cu²⁺/Zn²⁺ superoxide dismutase, protection against early diabetic glomerular injury in transgenic mice by, 2114

Author Index

A
Aalinkeel, R., 2053
Aarnio, P., 1834
Abbott, C.R., 2540
Abella, A., 2061
Abiru, N., 1274
Abood, M.E., 992
Abraham, E.J., 521
Abraham, L., 2384
Abu-Amro, S.N., 199
Accili, D., 1627
Adams, J.M., 2572
Adzet, T., 1883
Afione, S., 515
Agarwal, A., 515
Aguilar-Bryan, L., 322
Ahlberg, S., 2410
Ahlman, B., 947, 2652
Ahrén, B., 1030, 1539, 1959,
 2225
Aiello, L.P., 444
Aizawa, S., 1455
Aizawa-Abe, M., 227, 1440
Akunuma, Y., 1455
Åkerblom, H.K., 2625
Albers, J.J., 1851
Alegret, M., 1883
Alexander, M., 2355
Alexandre, H., 143
Ali, A., 1546
Allen, E.J., 2487
Allen, J., 2047
Almgren, P., 2402
Alt, A., 255
Altan, V.M., 455
Altavilla, D., 667
Amankwah, A.A., 2169
Amiel, S.A., 1618, 2329
Amit, M., 1691
Ämmälä, C., 329
Amri, K., 1069
Anai, M., 573
Andersen, H.U., 1056
Andersson, A., 301, 489
Ando, K., 573
Andrassy, M., 2792
André, J., 2809
Andreelli, F., 1134
Andreoli, A.M., 1414
Andrew, C.M., 1618
Andy, J., 2355
Angius, E., 1200
Anno, T., 1166
Antinozzi, P.A., 1791
Antonelli, A., 985
Antony, I., 1180
Anversa, P., 1414, 2363
Anyamale, V., 2355
Aoki, M., 1472
Apelqvist, Å., 1799
Appel, M.C., 972
Appelskog, I.B., 797
Arch, J.R.S., 105
Argiolas, A., 1950
Ariel, I., 2763
Arildsen, H., 837
Arita, Y., 1126
Armitage, N., 2633
Armstrong, J.L., 720
Arner, P., 1604, 2225, 2410
Artero, M., 2619
Asakawa, A., 1206
Asano, T., 573
Ashcroft, F.M., 2253
Assady, S., 1691
Assimacopoulos-Jeannet, F.,
 803
Atkinson, M., 515, 2451
Atkinson, M.A., 1749
Atlan-Gepner, C., 462
Attali, J.-R., 1180
Auclair, M., 1378
Augustine, D., 2729
Austin, M., 2396
Austin, T.M., 1330
Avritch, D., 91
Awata, T., 891
Aynsley-Green, A., 329, 2763
Azzout-Marniche, D., 2425

B
Bach, F.H., 1983
Bachmann, O.P., 2579
Baier, L., 901
Baillé, D., 1562
Bain, S.C., 184, 1200
Baj, G., 752, 985
Baker, L., 322
Bakhos, N., 2673
Bandsma, R.H.J., 2591
Banfi, C., 1522
Bao, M., 2691
Barbano, D.M., 1149
Barber, R., 184
Barberà, A., 131
Bardelli, M., 2619
Barnes, P.D., 329
Barnett, A.H., 1200
Barrett, E., 2682
Barzilai, N., 348, 2786
Barzilay, J.I., 2384
Bashan, N., 1425
Basu, A., 565, 1351
Basu, R., 565, 1351
Battle, D., 1482
Batterham, R.L., 2540
Battezzati, A., 277
Bauman, D.E., 1149
Båvenholm, P.N., 1449
Beasley, J., 733
Beavers, L.S., 2822
Bécard, D., 2425
Becker, R., 876
Beck-Nielsen, H., 1324, 1363
Beguinot, F., 1244
Beisswenger, P.J., 2139
Bektaş, A., 204
Bell, G., 199
Bell, G.I., 694, 2013
Belsanti, G., 2709
Benedini, S., 277
Bennett, P.H., 1598, 2850
Bennett, S.T., 199
Bentley, B., 123
Berg, C., 947
Bergeron, R., 1076
Berggren, P.-O., 797
Berglund, L., 690
Bergman, R.N., 399, 886
Bergonzelli, G.E., 2666
Bergsten, P., 51, 1785, 2737
Berkovich, I., 2260
Berman, D.M., 2172
Berne, C., 690
Bernek, F., 2021
Berney, T., 270, 1983
Bernroider, E., 392
Berria, R., 2572
Bertruy-Coussé, L., 2425
Bertuzzi, F., 1290, 2464
Bianchi, G., 1844
Bidasee, K.R., 455
Biden, T.J., 2210, 2237
Bierhaus, A., 2792
Bigam, D., 710
Bingham, C., 2047
Binnert, C., 727
Bischof, L.J., 502
Bischof, M.G., 392
Bjørcke, R.J., 1495
Björnholm, M., 2770
Blaak, E.E., 2548, 2870
Blair, L.A., 283
Bleich, D., 1047
Bloom, S.R., 248, 2540
Bock, T., 1553, 1763
Boden, G., 810, 1612
Bodkin, N.L., 1126
Boehnke, M., 886
Boeri, D., 1432
Boettcher, B.R., 1813, 2287
Bogardus, C., 901, 1828
Bohlooly-Y, M., 1539
Boirie, Y., 2652
Boitard, C., 1211
Bolinder, J., 1604
Bona, G., 483
Bonavaud, S.M., 720
Bondjers, G., 2126
Bonifacio, E., 2451, 2464
Bonini, P., 1290
Bonissoni, S., 483
Bonner-Weir, S., 2231
Bonny, C., 77
Borghouts, L.B., 2870
Bornfeldt, K.E., 851
Bortolotto, M., 2619
Bosco, D., 1039
Bosi, E., 2464

C
Cabrero, A., 1883
Cadario, F., 483
Cai, T., 2406
Cai, X.J., 105
Caillat-Zucman, S., 1211
Cairns, F., 2148
Camargo, C.A., Jr., 2390
Cambien, F., 1214
Camejo, G., 2126
Camilleri, M., 565
Campo, G.M., 667

Candido, R., 2619
 Candigliota, M., 159
 Capeau, J., 1378
 Caplan, S.L., 1813, 2287
 Capulong, E., 810
 Caradonna, Z., 1290
 Carandente, O., 1290
 Cardin, S., 558, 1872, 2487
 Cardozo, A.K., 909, 2219
 Carlson, E.C., 2040
 Carlsson, M., 675
 Carlsson, P.O., 489
 Caro, J.F., 2822
 Caron, M., 1378
 Carpéné, C., 2061
 Carpenter, L., 2210, 2237
 Carpenter, A., 1402
 Carr, J.J., 861
 Carraro, M., 2619
 Garretta, R., 2619
 Carruba, M.O., 601
 Caruso, M., 1244
 Cases, J.A., 348
 Cassader, M., 752
 Castellani, L.W., 643
 Cattan, P., 270, 1983
 Cattin, M.R., 2619
 Cattral, M.S., 1402
 Cavadas, C., 2666
 Cavaghan, M., 1828
 Cavaghan, M.K., 150
 Cavallari, V., 667
 Cavallo-Perin, P., 752
 Cayeux, C., 727
 Cazzolli, R., 2210
 Cebrian, A., 2752
 Cerasi, E., 308, 1799
 Ceravolo, R., 159
 Cersosimo, E., 2087
 Cerutti, F., 483
 Cesselli, D., 2363
 Cha, S., 2100
 Chagnon, M., 614
 Chagnon, Y.C., 614, 697
 Chan, C.B., 1302
 Chan, G., 675
 Chan, S.L.F., 340
 Chandramouli, V., 1872
 Chang, C.J., 2815
 Chang, J.-C., 2598
 Chang, T.-J., 2598
 Chapman, H.D., 1992
 Chapman, J.C., 329
 Chardes, T., 1311
 Charlton, M., 947, 2652
 Charron, M.J., 1149
 Chatenoud, L., 2459
 Chatham, J.C., 1171
 Chatterjee, V.K.K., 686
 Chayen, S., 681
 Chen, H., 2040
 Chen, H.-Q., 1580
 Chen, J., 2792
 Chen, W., 1863
 Chen, X., 810
 Cheng, J.-T., 1206, 2815
 Chernausek, S.D., 1110
 Cherrington, A.D., 367, 558, 622, 1872, 2487
 Chesnut, K., 515
 Cheung, S., 1918
 Chi, T.-C., 2815

Chiba, S., 376, 385
 Chiba, Y., 573
 Childhood Diabetes in Finland Study Group, the, 2625
 Chimenti, S., 1414
 Chiu, P.P.L., 763
 Choi, C.S., 418
 Choi, J.Y., 2837
 Chong, M.M.W., 2744
 Christiansen, E., 2611
 Christiansen, J.S., 96, 2301
 Chu, S.C., Jr., 425
 Chuang, L.-M., 2598
 Chung, M.H., 2837
 Cirillo, G., 2157
 Cisternino, C., 1950
 Civelek, V.N., 56
 Clark, M.G., 2659
 Claussen, C.D., 2579
 Clemmons, D.R., 32
 Clermont, A., 444
 Cline, G.W., 1076, 1263
 Cnop, M., 1771, 2514
 Cobelli, C., 150
 Coffey, C.S., 558
 Coggins, M., 2682
 Coghlann, M., 937
 Cohen, M.A., 2540
 Colhoun, H.M., 652
 Collins, F.S., 886
 Collins, M.D., 1193
 Colonna, M., 667
 Combatsiaris, T., 1149
 Compston, A., 184
 Condorelli, G., 1244
 Conigrave, K.M., 2390
 Connell, J.M.C., 2148
 Connolly, S., 1813, 2287
 Conner, L.J., 2822
 Considine, R.V., 2199
 Contreras, J.L., 1227
 Cook, J.A., 1330
 Coon, B., 2700
 Cooney, G.J., 411
 Cooper, G.J.S., 1821
 Coppey, L.J., 1927
 Coraddu, F., 184
 Corbett, J.A., 283
 Cordell, H., 1200
 Cordell, H.J., 184
 Cordi, S., 143
 Corkey, B.E., 56
 Corominola, H., 2822
 Corrias, A., 483
 Cosgrove, K.E., 329
 Costanzo, B.V., 831
 Courtoy, P.J., 143
 Cox, N.J., 694, 2013
 Cranston, I., 2329
 Cras-Méneur, C., 1219, 1571
 Craven, P.A., 2114
 Cristallo, M., 496
 Cristobal, C.P., 824
 Cristofalo, V., 2641
 Crook, E.D., 2355
 Cros, G., 2164
 Croset, M., 740
 Crow, M.T., 1495
 Cruz, W.S., 353
 Cryer, P.E., 1911
 Cucca, F., 184, 1200
 Cucinotta, D., 667

Cui, L., 1149
 Cummings, D.E., 1714, 2555
 Currie, K.P.M., 2013
 Cushman, M., 2384
 Cushman, S.W., 593
 Cusi, K., 2572
 Cusin, I., 601
 Cuthbertson, D., 470
 Cuthbertson, D.D., 1735
 Czernichow, P., 1571, 2021

D
 Da Costa, A., 1720
 Dahl, D.B., 2579
 Dahlmans, V.E.H., 2585, 2779
 Damaris Molano, R., 1706
 Damberg, G.S., 2203
 Damotte, D., 2874
 Damsgaard, E.M., 630
 D'Angelo, A., 496
 Daniel, P.B., 521
 Danielsen, P., 1588
 Danoy, P.A., 184
 Danska, J.S., 763
 Darville, M., 2219
 Darville, M.I., 1741
 Daurès, J.P., 2164
 Davallil, A.M., 1290, 2709
 Davidoff, A.J., 1186
 Davidson, E.P., 1927
 Davidson, M.B., 1186, 1222
 Davis, H.R., 1330
 Deacon, C.F., 609, 1588, 2497
 Deeney, J.T., 56
 Defoort, C., 462
 DeFranco, S., 483
 DeFrongo, R.A., 2572
 DeHaven, J.E., 2419
 De Hertogh, R., 143
 Dela, F., 1834
 del Bosque-Plata, L., 694
 Delenne, B., 462
 De Leo, D., 1302
 del Giudice, E.M., 2157
 Del Maschio, A., 496
 Del Parigi, A., 901
 De Matos, F., 1219
 Dence, C.S., 1911
 Denner, L., 1495
 Dennis, K.E., 2172
 Deodato, B., 667
 Depaz, H.A., 1546
 D'Ercole, A.J., 32
 DeRubertis, F.R., 2114
 Desai, U.J., 1813, 2287
 de Souza, C.J., 1863
 Després, J.-P., 614
 Devanarayan, V., 707
 De Virgiliis, S., 1200
 Dhalla, N.S., 2133
 Dhillo, W.S., 2540
 Diabetes Prevention Trial of Type 1 Diabetes Study Group, 470
 Dianzani, U., 483
 Di Carlo, V., 277, 496
 Dietz, S., 1311
 Diez, J., 895
 Dillon, J.S., 56
 DiLorenzo, T.P., 1992
 Dinçer, Ü.D., 455
 Dionne, L.J., 91

Di Paola, R., 831, 1950
 Di Toro, R., 2157
 Dixon, K., 622
 Dobashi, R., 1206
 Dobbins, R.L., 123
 Docherty, K., 2244
 Domínguez, J., 131
 Dominiczak, A.F., 2148
 Donath, M.Y., 69, 1683, 2105
 Donelan, M.J., 2029
 Dong, M., 1863
 Donnay, I., 143
 Donovan, C.M., 399
 Doria, A., 204
 Dorman, J.S., 1857
 Douglas, J.A., 886
 Doyle, P.J., 411
 DPT-1 Participating Investigators, the, 1735
 Drucker, D., 1720
 Du, X.-l., 1491
 Dubois-Laforgue, D., 1211
 Ducluzeau, P.-H., 1134
 Ducret, R., 1336
 Dudbridge, F., 1200
 Dumas, F., 1666
 Dunlap, J.A., 1927
 Dunne, M.J., 329
 Dupont, S., 1219
 DuPrat, L., 681
 D'Urso, L., 2157
 Dutta, K., 1186
 Duvivier-Kali, V.F., 1698
 Dyntar, D., 69, 2105

E
 Eaves, I.A., 184
 Ebbehøj, E., 837
 Ebihara, K., 227, 1440
 Eckel, R.H., 1064
 Eckhard, M., 277
 Eckhardt, M., 1863
 Eckhoff, D.E., 1227
 Edelstein, D., 1491
 Edgerton, D.S., 558, 1872
 Edlund, H., 1799
 Edwards, K., 2396
 Efanov, A.M., 797
 Efendic, S., 308, 797, 1449
 Efrat, S., 980, 2260
 Egnell, A.-C., 2126
 Ehnholm, C., 886
 Eisenbarth, G., 2451
 Eisenbarth, G.S., 895, 1274, 1735
 Eizirik, D.L., 909, 1741, 1771, 2219
 Ekberg, I., 921
 Eldar-Finkelman, H., 1171
 Elghazi, L., 1571, 2021
 Elimban, V., 2133
 Ellard, S., 2047
 Elliott, J.F., 710
 Ellis, T., 515
 El Mkadem, S.A., 2164
 Eloy, L., 2874
 Elrick, L.J., 2244
 Embury, J., 1706
 Emoto, M., 1166
 Emshwiller, M., 367, 1872
 Endl, J., 1749
 Engerman, R.L., 1636

Eppenberger, H.M., 2105
 Eppenberger-Eberhardt, M., 2105
 Epstein, P.N., 2040
 Ercolino, T., 1950
 Erdos, M.R., 886
 Eriksson, J.W., 2344
 Eriksson, P., 1522
 Erkinjuntti, M., 1371
 Esser, V., 123
 European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT) Study Group, 843
 Evans, J.L., 404
 Evans, M., 1618
 Evans, M.L., 105

F
 Fabris, B., 2619
 Fabris, R., 601
 Faccini, L., 2619
 Fakhrai-Rad, H., 2737
 Fallahi, P., 985
 Fanelli, B., 1813, 2287
 Fanelli, C.G., 1911
 Fantus, I.G., 83, 2376
 Farley, C., 1330
 Fasy, E., 2682
 Federici, M., 1290
 Federspil, G., 601
 Feener, E.P., 444
 Fekkes, M.L., 1237
 Feng, Z., 2786
 Fenjves, E.S., 515
 Ferber, S., 1799
 Fermo, I., 496
 Fernandez, A.M., 1110
 Fernández-Alvarez, J., 131
 Ferrannini, E., 985, 1807
 Ferrante, A.W., Jr., 2268
 Ferré, P., 2425
 Ferreira, L.D.M.C.-B., 1064
 Ferretti, J., 2087
 Ferry, R.J., Jr., 322
 Fey, S.J., 1056
 Filipsson, K., 1959
 Finegood, D.T., 1021
 Fink, B.D., 1119
 Finnerty, J., 534
 Fior, F., 2619
 Fiordaliso, F., 1414, 2363
 Fiorina, P., 496
 Fiorotto, A., 2619
 Fisher, J., 1397
 Flattem, N., 367
 Fledelius, C., 2530
 Fleischer, N., 348
 Flotte, T., 515
 Fluteau, G., 2874
 Foisy, S., 2237
 Foley, T.P., 1857
 Folli, F., 1290
 Fontana, A., 1683
 Ford, G.C., 747
 Forest, C., 1378
 Forlani, G., 1844
 Formisano, P., 1244
 Forsblom, C., 675
 Foufelle, F., 2425
 Fox, A.P., 2013
 Fraker, C., 1706, 1983
 Francis, M.K., 2641
 Frascerra, S., 1807
 Frayo, R.S., 1714
 Freedman, B.I., 861
 Freund, N., 1069
 Frias, J.P., 1344
 Friel, E., 291
 Friemanu, S., 277
 Fritzsche, A., 882, 1143, 2161
 Frittitta, L., 831, 1950
 Fritz, G., 1643
 Fröberg, S., 921
 Froguel, P., 1219
 Frøland, A., 630
 Fruchart, J.-C., 2809
 Frystyk, J., 1110
 Fu, A., 947
 Fujii, N., 241, 921
 Fujimiya, M., 1206
 Fujimoto, Y., 622
 Fujishiro, M., 573
 Fujita, T., 573
 Fujitani, Y., 2864
 Fukushima, Y., 573
 Fuller, J.H., 652
 Funabiki, K., 1943
 Funahashi, T., 1126, 2094
 Funaro, A., 752
 Fürnsinn, C., 2309
 Furuta, H., 2864
 Furuta, M., 534
 Furutani, Y., 113
 Futers, T.S., 1505, 2646

G
 Gabriely, I., 348
 Gadski, R.A., 2822
 Gagen, K., 1863
 Gaillard, R.C., 2666
 Gale, E.A.M., 217
 Galeano, M., 667
 Galíñanes, M., 2603
 Galitzky, J., 2080
 Galli, J., 2737
 Galuska, D., 1149
 Garchon, H.-J., 2874
 García-Ocaña, A., 2752
 Garlick, P., 2087
 Garrovillo, M., 1546
 Gartsbein, M., 255, 1627
 Garza, D., 895
 Gastaldelli, A., 1807
 Gaster, M., 1324
 Gautier, J.-F., 1828
 Gavrilova, O., 1440
 Gellett, J.S., 1927
 Geoghegan, K.F., 2029
 Gerhardinger, C., 175
 Gerich, J.E., 905
 Gerin, I., 1531
 Gerlach, M.J., 521
 German, M.S., 63, 694, 928
 Gerrity, R.G., 851, 1654
 Gertz, S.J., 2279
 Ghatei, M.A., 248, 2540
 Ghitescu, L.D., 1666
 Giacca, A., 1402
 Giampietro, V., 1618
 Giandomenico, G., 1522
 Gibbons, G.H., 1171
 Gibbs, E.M., 593
 Gilchrist, F., 1200
 Giorgino, F., 2709
 Giorgino, R., 2709
 Giunti, S., 752
 Gjessing, H.J., 630
 Glaser, B., 322, 329, 681, 2763
 Glatter, O., 1643
 Glauser, M., 2666
 Gleason, C.E., 2481
 Glimcher, L.H., 39
 Glorian, M., 1378
 Goforth, P.B., 992, 2192
 Goldberg, H.J., 2376
 Goldfine, A.L., 404
 Goldfine, I.D., 824, 2323
 Goldman, J.K., 502
 Goldstein, B.J., 83
 Gomis, R., 131
 Gonelle-Gispert, C., 1039
 Gonzalez, C., 2874
 Gonzalez, F.J., 2809
 Goodyear, L.J., 241, 921
 Gopinathan, R., 1546
 Goran, M.I., 2444
 Goto, A.M., 643
 Goto, T., 2337
 Gotoda, T., 891
 Gould, G.W., 2148
 Gourdon, L., 1515
 Gower, B.A., 2444
 Graci, S., 1950
 Graham, T., 2349
 Graier, W., 1643
 Grant, P.J., 1505, 2646
 Granzotto, M., 601
 Gras, F., 2309
 Graser, R.T., 1992
 Gray, D., 91
 Greenbaum, C.J., 470
 Greenberg, A.S., 1425
 Greene, K., 2355
 Greenhaff, P.L., 18
 Greer, F., 2349
 Greiner, D.L., 972
 Gribble, F.M., 2253
 Griffen, S.C., 63
 Grigorescu, F., 2164
 Grimberg, A., 322
 Grimsby, J., 622
 Grippo, J.F., 622
 Gris, J.C., 2164
 Groop, L.C., 675, 2402
 Gross, D.J., 1799
 Gross, R., 1311
 Grouzmann, E., 2666
 Gruetter, R., 2203
 Guerre-Millo, M., 2809
 Gugliucci, A., 1666
 Guinovart, J.J., 131
 Güner, S., 455
 Gunther, V.J., 2287

H
 Ha, X.F., 1302
 Haap, M., 2579
 Habener, J. F., 521, 1553
 Hagström-Toft, E., 1604
 Haidacher, J., 1495
 Hainault, I., 2425
 Häkinen, A.-M., 2337
 Halavaara, J., 2337
 Halban, P.A., 1039, 2181
 Halestrap, A.P., 361
 Hall, J.L., 1171
 Halsall, D.J., 686
 Halse, R., 720, 1102
 Hamaguchi, K., 1012
 Hamilton, J.A., 56
 Hammes, H.-P., 2641
 Hamsten, A., 1522
 Han, B., 2837
 Han, X., 1047
 Hanabusa, T., 2864
 Hanafusa, T., 891, 1269
 Handberg, A., 1324
 Hani, E.H., 1219
 Hanis, C.L., 2013
 Hanna, L.S., 2842
 Hanna, S.T., 166
 Hannaert, J.C., 1771
 Hänninen, A., 771
 Hansen, Å.P., 1778
 Hansen, B.C., 1126
 Hansen, B.F., 584
 Hansen, K.W., 837
 Hansen, L., 690
 Hansen, L.L., 584
 Hansen, P.A., 2013
 Hansen, T., 690
 Hanson, R.L., 1598, 2850
 Hara, K., 891
 Harada, S., 2169
 Harbis, A., 462
 Harding, A.-H., 686
 Hardy, M.A., 1546
 Hargrove, D.M., 593
 Häring, H., 876, 882, 1143, 2161, 2579, 2792
 Harman-Boehm, I., 1425
 Harmon, J.S., 315, 2481
 Harper, I., 901
 Harrison, L.C., 771, 2459
 Haruta, T., 1083, 1891
 Haskins, K., 2459
 Hastings, J.R., 2487
 Hata, Y., 444
 Hattersley, A.T., 2047
 Havekes, L.M., 2585, 2779
 Haversle Foss, C., 630
 Hayashi, M., 1012, 1464
 Hayashi, T., 227, 1093, 1440, 2296
 Haynes, W.G., 1119
 He, J., 817
 Heath, W.R., 771
 Heckbert, S.R., 2384
 Heilmann, C., 1056
 Heiman, M.L., 707
 Heimberg, H., 1, 2219
 Heitmeyer, M.R., 283
 Heller, R.S., 1553
 Hemmings, B.A., 690
 Henchoz, E., 727
 Hendel, H., 1211
 Henle, T., 2792
 Henquin, J.-C., 540
 Heremans, Y., 2219
 Herlein, J.A., 1119
 Herling, A.W., 2591
 Hernandez, R., 2563
 Herold, K., 980
 Hespel, P., 18
 Hesselink, M.K.C., 2870
 Heutink, P., 637
 Hevener, A.L., 399, 2316

Higaki, Y., 241
 Higo, K., 139
 Hirhart, M., 1755
 Hirose, S., 1943
 Hirshman, M.F., 241, 921
 Ho, I.-C., 39
 Hobbs, G.R., 436
 Hoeldtke, R.D., 436
 Hoffstedt, J., 2410
 Hofman, A., 637
 Hofmann, M., 2792
 Ho-Kim, M.-A., 614
 Holloszy, J.O., 1397
 Holm, C., 2225
 Holman, G.D., 12
 Holmdahl, R., 184
 Holness, M.J., 2729
 Holst, J.J., 565, 609, 776, 1030,
 1363, 1588, 2497
 Homko, C., 1612
 Honda, Y., 867
 Hong, M., 2792
 Hoorens, A., 551, 1771
 Hopkins, D., 1618
 Horikawa, Y., 694, 2013
 Horn, T., 1553
 Hornbuckle, L.A., 502
 Horvath, G.G., 436
 Horwitz, M., 980
 Hosoda, K., 227, 1093, 1440,
 2296
 Hother-Nielsen, O., 1363
 Hotta, K., 1126, 2094
 Hou, L., 2169
 Houseknecht, K.L., 1149
 Hovland, D.N., Jr., 1193
 Howell, S., 2139
 Hribal, M., 1290
 Hsu, W.H., 2598
 Hu, B.F., 2390
 Hua, H., 2376
 Hubbard, W.J., 1227
 Hücker, K., 2497
 Hudson, B.I., 1505, 2646
 Hudson, R., 2349
 Hughes, A., 2700
 Hughes, J.N., 204
 Hui, H., 785
 Hull, R.L., 2514
 Humpert, P.M., 2792
 Humphreys-Beher, M.G., 2100
 Hurot, J.-M., 740
 Hussain, K., 2763
 Hutton, J., 895
 Hutton, J.C., 502, 1729
 Huypens, P., 1
 Hyrkkö, A., 675

I
 Iacopino, S., 159
 Igawa, K., 367
 Iglesias, M.A., 411
 Ihlemann, N., 2611
 Ikeda, Y., 584
 Ikegami, H., 891
 Iliadou, A., 2410
 Imagawa, A., 1269
 Imes, S., 710
 Inoue, G., 227, 1093, 1440, 2296
 Inoue, I., 891
 Inoue, R., 1093
 Inui, A., 1206

Inukai, K., 573
 Inverardi, L., 270, 515, 1706,
 1983
 Ionesco-Tirgoviste, C., 184
 Isaksson, O.G.P., 1539
 Ishibashi, O., 1083
 Ishii, S., 2438
 Itoh, N., 1269
 Itskovitz-Eldor, J., 1691
 Iwashita, H., 1269
 Iwamoto, Y., 694, 891
 Iwasaki, N., 694, 891
 Iwata, M., 1083, 1891

J
 Jacinto, S.M., 1158
 Jackson, P.A., 558
 Jackson, R., 1735
 Jacob, C.O., 184
 Jacob, H.J., 2521
 Jacob, S., 876, 2579
 Jacques, H., 1901
 Jahn, L., 2682
 James, A.J., 2047
 James, D.J., 2148
 Janez, A., 2316
 Janssen, J.A., 637
 Jansson, J.-O., 1539
 Jansson, P.-A.E., 2344
 Jauniaux, E., 199
 Jayaraman, S., 1706
 Jenkins, S., 1227
 Jenkins, C., 901, 2572
 Jensen, C.B., 2770
 Jensen, D.R., 1064
 Jensen, J., 1553
 Jensen, M., 1351
 Jéquier, E., 727
 Jessen, N., 12
 Jetton, T.L., 622
 Jin, M.-X., 1546
 Jirholz, J., 184
 Joannis, D.R., 195
 Jobin, C., 2219
 Johnson, C.M., 1351
 Johnson, D., 2822
 Johnson, E.A., 980, 1992
 Johnston, C.L., 886
 Joner, G., 2879
 Jong, M.C., 2585, 2779
 Jonkers, F.C., 540
 Jørgensen, J.O.L., 96, 2301
 Joseph, J.W., 1302
 Joyce, S., 1992
 Juhasz, O., 1495
 Juhel, C., 462
 Juhl, C., 776
 Juhl, C.B., 1778
 Jury, K., 1976

K
 Kaburagi, Y., 1455
 Kadowski, T., 113, 891, 1455
 Kaga, T., 1206
 Kähler, H., 1056
 Kahn, A., 1515
 Kahn, S.E., 2181, 2514
 Kaiser, N., 69, 308, 1683, 1799
 Kajimoto, Y., 2864
 Kajio, H., 2029
 Kajstura, J., 1414, 2363
 Kaleko, M., 1813, 2287
 Kalsbeek, A., 1237

Kamegai, J., 2438
 Kaneda, Y., 1472
 Kang, B.P.S., 1918
 Kangawa, K., 227
 Kapturczak, M., 515
 Karhapää, P., 1949
 Kärkkäinen, P., 1949
 Karlsen, A.E., 1056
 Kasper, M., 2792
 Kassem, S.A., 2763
 Kassis, N., 2874
 Kasuga, M., 891, 1206
 Kato, H., 113
 Kato, K., 113
 Kaufman, D.L., 2459
 Kaul, S., 2682
 Kawaguchi, Y., 891
 Kawahara, J., 1083, 1891
 Kawanaka, K., 1397
 Kawata, S., 1269
 Kay, T.W.H., 2451, 2744
 Keizer, H.A., 2870
 Kekäläinen, P., 1949
 Kelemen, K., 1729
 Kelley, D.E., 817, 1253, 2069
 Kelly, A., 322
 Kelpe, C.L., 315
 Kendall, D.M., 47
 Kent, A., 2133
 Kenyon, N., 1706
 Kenyon, N.S., 270
 Kergoat, M., 1562
 Kern, T.S., 1636, 1938
 Khan, A., 308
 Khan, F.A., 2192
 Kieffer, T.J., 1004
 Kiens, B., 265
 Kihara, S., 2094
 Kikuchi, M., 573
 Kim, J.H., 2837
 Kim, J.M., 2837
 Kim, M.S., 248, 2837
 Kim, S., 1472
 Kim, S.K., 2837
 Kim, S.Y., 2837
 Kimsey, T., 1654
 Kimura, S., 113, 1455
 Kin, T., 710
 Kinard, T.A., 992
 Kingsnorth, A., 199
 Kirby, B.M., 2001
 Kishida, K., 2094
 Kistorp, C.N., 2611
 Kjems, L.L., 2001
 Klarskov, L., 1588
 Klein, D., 1706
 Klenk, E.S., 2199
 Klip, A., 1464
 Klöting, I., 2792
 Kneteman, N.M., 710
 Knip, M., 2625
 Knowler, W.C., 1598, 1828, 2850
 Knudsen, L.B., 2530
 Knudsen, S.T., 837
 Knuuti, M.J., 1371
 Kobayashi, M., 1083, 1891, 1943
 Kober, L., 2611
 Kobes, S., 2850
 Koch, M., 882
 Koleman, B.P.C., 1200
 Kohanski, R.A., 824
 Kojima, M., 227

Kojwang, D., 1021
 Komuro, R., 2094
 Kono, D.H., 184
 Konrad, D., 1464
 Koo-McCoy, S., 322
 Korbutt, G.S., 710
 Korchak, H.M., 56
 Korsgren, O., 962
 Korsheninnikova, E., 2337
 Kostner, G.M., 1643
 Kowalski, T.J., 425
 Kowluru, A., 1580
 Kowluru, R.A., 1938
 Koyama, S., 867
 Kozlowski, M., 2323
 Kozlowski, M.R., 824
 Kraegen, E.W., 411, 1821
 Kraemer, F.B., 1455
 Krakoff, J., 1598
 Kramer, D.L., 24
 Krarup, T., 609, 2611
 Kratky, D., 2585
 Krebs, M., 392
 Krischer, J.P., 470, 1735
 Krolewski, A.S., 204, 2842
 Krssak, M., 392
 Kruhoffer, M., 909
 Krusynska, Y.T., 1344
 Kubota, N., 1455
 Kuchinski, N., 329
 Kuipers, F., 2591
 Kuller, L.H., 1857, 2384
 Kulmala, P., 2625
 Kuriyama, H., 2094
 Kuroki, T., 255
 Kuusisto, J., 1949
 Kvist-Reimer, M., 1959
 Kwok, C.K., 1857
 Kwon, G., 353

L
 Laakso, M., 1949, 2396
 Läärä, E., 2625
 Laborde, E., 824
 Lacaille, M., 614
 Laffel, L.M.B., 2842
 La Fleur, S.E., 1237
 Lafontan, M., 2080
 Laguna, J.C., 1883
 Lai, R., 83
 Lairon, D., 462
 Lajoix, A.-D., 1311
 Lakey, J.R.T., 710
 Lamberts, S.W.J., 637
 Lameloise, N., 803
 Lamhammedi-Cherradi, S.-E.,
 2874
 Lampis, R., 1200
 Landau, B.R., 1872
 Langefeld, C.D., 861
 Lanz, K.J., 47
 La Rocca, E., 496
 Larsen, I., 710
 Larsen, M.R., 1056
 Larsen, P.J., 2530
 Larsen, P.M., 1056
 Larsson, O., 797
 Latgé, C., 462
 Laurent, D., 1263, 1863
 Lauritsen, T., 1834
 Lauro, R., 1290
 Lautier, C., 2164

Laval, S., 184
 Lavebratt, C., 2410
 Lavigne, C., 1901
 Laville, M., 1134
 Laviola, L., 2709
 Lawrence, J.C., Jr., 404
 Laychock, S.G., 2505
 Le, N., 1397
 Lebed, B., 1612
 LeBoeuf, R.C., 2555
 Leclerc, I., 1515
 Lecoeur, C., 1219
 Ledoux, S., 1180
 Lee, F.N., 418
 Lee, H.K., 2837
 Lee, J.C., 928
 Lee, J.-P., 2013
 Lee, M.R., 2126
 Lee-Chan, E., 2451
 Leeman, R., 909
 Leemans, R., 2219
 Lefebvre, P., 2001, 2164
 Lehmann, R., 1683
 Lehtovirta, M., 675
 Leibel, R.L., 425, 2268
 Leibowitz, G., 1799
 Lelièvre-Pégorier, M., 1069
 Lemieux, S., 614, 1612
 Lenzi, M., 1844
 Lenzner, C., 1515
 Leonard, T., 1021
 Leri, A., 1414, 2363
 Lermark, Å., 2181
 Le Roith, D., 1110
 Leslie, R.A., 105
 Leslie, R.D.G., 2858
 Le-Tien, H., 83
 Levak-Frank, S., 1643, 2585
 Levin, B.E., 2673
 Levin, K., 1363
 Lévi-Strauss, M., 2874
 Lewis, G.F., 1402
 Lewitzky, S., 675, 681
 Li, B., 1414
 Li, H., 270, 1970
 Li, M., 2323
 Liao, T., 2268
 Lillaz, E., 752
 Limana, F., 1414, 2363
 Lin, J., 681, 694, 928
 Lin, J.-M., 2737
 Lindgren, C., 675
 Lindgren, C.M., 2402
 Lindley, K.J., 329, 2763
 Lindner, J., 2682
 Lindsay, R.S., 1598, 2850
 Liss, P., 489
 Lister, C.A., 105
 Lithell, H., 690
 Liu, I.-M., 2815
 Liu, I-Min., 1206
 Liu, J.-L., 1110, 1539
 Liu, M.-W., 2598
 Liu, S.-M., 425
 Liu, X.H., 2431
 Ljung, B., 1158
 Ljungqvist, O., 921
 Lo, D., 39
 Lobashevsky, A., 1227
 Lobbens, S., 1219
 Löblein, K., 876
 Lochhead, P.A., 937
 Loddo, M., 1200
 Loffredo, G., 483
 Loiler, S., 515
 Lombardi, A.M., 601
 López-Talavera, J.-C., 2752
 Lord, C.J., 2633
 Lorentzon, M., 2126
 Lorenzi, M., 175, 1432
 Lorenzo, M., 2563
 Loviscach, M., 2579
 Lu, F.-H., 2815
 Luan, J., 686
 Lukinius, A., 962
 Lum, R.T., 824
 Lund, D.D., 1927
 Lund, S., 12
 Lundén, G.Ö., 2126
 Lusis, A.J., 643
 Luther, T., 2792
 Luthman, H., 2737
 Luzi, L., 277
 Lynn, F.C., 1004
 Lyons, P.A., 2633

M

Ma, X.H., 348
 Macaraeg, G.B., 1344
 Macari, F., 2164
 Machado, A.F., 1193
 Machann, J., 2579
 Machicao, F., 876, 882, 2161
 Maclare, N., 1735
 Madaus, A., 882, 2161
 Maddux, B.A., 404, 2323
 Madsbad, S., 609, 2770
 Madsen, O.D., 1553
 Maeda, E., 891
 Maeda, N., 2094
 Maedler, K., 69, 1683, 2105
 Maerker, E., 882
 Maezono, K., 2572
 Maffi, P., 2464
 Maggi, L.B., Jr., 283
 Magnus, P., 2879
 Magnuson, M.A., 622
 Maiello, M., 1432
 Maier, T., 2579
 Maitan, M.A., 1244
 Major, C.D., 2721
 Makimura, H., 733
 Malavasi, F., 752, 985
 Malhotra, A., 1918
 Mallone, R., 752
 Manchem, V.P., 824, 2323
 Mandarino, L.J., 2572
 Maniatis, A.K., 1274
 Manteghetti, M., 1311
 Maor, G., 1691
 Marchesini, G., 1844
 Marchetti, P., 985, 1290
 Marette, A., 1901
 Markham, J., 1911
 Marlier, L.N.J.L., 1290
 Marounek, J., 972
 Marron, M.P., 1992
 Marrosu, M.G., 184
 Marsden, P.K., 2329
 Marshall, C.A., 353
 Marti, L., 2061
 Martin, C.C., 502
 Maruti, S., 681
 März, W., 776

Masaki, T., 376, 385
 Masiello, P., 1970
 Masuzaki, H., 1093, 1440
 Matata, B.M., 2603
 Matsubara, H., 1472
 Matsuda, M., 2094
 Matsutani, A., 891, 1166
 Matsuzawa, Y., 1126, 1269, 2094
 Mattioli, P.L., 159
 Matzinger, O., 727
 McArdle, J.J., 2673
 McArthur, M.D., 1021
 McClure, K.D., 175
 McCoid, S.C., 593
 McCormack, J.G., 720, 1102
 McCullough, A.J., 1844
 McDaniel, M.L., 353
 McGarry, J.D., 123
 McIntosh, C.H.S., 1004
 McIntyre, S.S., 2001
 McKnight, G.S., 2555
 McQuaid, T.S., 1302
 Medow, M.S., 1414
 Meggs, L.G., 1918
 Meier, J.J., 2497
 Meijer, A.J., 2591
 Meile, M.-J., 1562
 Mejia, W., 1110
 Melchionda, N., 1844
 Melhem, M.F., 2114
 Melino, G., 1290
 Melloul, D., 1799
 Mensink, M., 2548
 Merlet-Bénichou, C., 1069
 Merriman, T.R., 184
 Mest, H.-J., 797
 Meyer, A. Parker, J., 675
 Meyer, J., 681
 Miao, D., 1274
 Michaeli, T., 348
 Michaud, S.É., 660
 Miele, C., 1244
 Miettinen, R., 1949
 Miles, P.D.G., 139
 Milla, C., 1336
 Miller, C.P., 1553
 Millevoi, C., 2619
 Minehira, K., 727
 Minicucci, F., 496
 Mirnra, R.G., 928
 Mitchell, G.A., 1970
 Mitchell, J.R.D., 248
 Mithieux, G., 740
 Miyagawa, J.-i., 1269
 Miyanaga, F., 227, 1440
 Mizuno, T.M., 733
 Mobbs, C.V., 733
 Moberg, E., 1604
 Modrick, L.M., 1580
 Mogensen, C.E., 630, 837
 Möhlig, M., 2641
 Mohlke, K.L., 886
 Möhrle, U., 2700
 Molano, R.D., 270, 1983
 Mølgård, H., 837
 Molinari, N., 2164
 Møller, N., 96, 747, 2301
 Montano, S., 740
 Moore, A., 2231
 Moore, G.E., 199
 Moran, A., 1336
 Morcos, M., 2792

Mordes, J.P., 972
 Morgan, D.A., 1119
 Morgan, D.G.A., 248
 Morgan, K., 2786
 Morgan, N.G., 340
 Mori, H., 891
 Morimoto, Y., 1206
 Morishita, R., 1472
 Moritz, J.T., 2040
 Moritz, W., 69, 521
 Moriawaki, M., 1269
 Moriyama, H., 1274
 Moriyama, Y., 1012
 Morris, R., 2431
 Mosthof-Seedorf, L., 584
 Mott, D., 1828
 Mourtada, M., 340
 Mozzoli, M., 810
 Mulargia, A.P., 1200
 Müller, B., 521
 Munoz, K.N., 2472
 Muñoz, M.C., 131
 Murphy, G.J., 2148
 Murphy, K., 248
 Murphy, L.J., 32
 Musi, N., 921
 Mussoni, L., 1522
 Muurling, M., 2779
 Muzzin, P., 803
 Myhill, J., 123
 Mykkänen, L., 1949

N

Nadal-Ginard, B., 1414, 2363
 Nadeau, A., 697
 Nadler, J.L., 1654
 Nagaretani, H., 2094
 Nagashima, H., 2100
 Nagy, A., 2100
 Nair, K.S., 96, 747, 947, 1336,
 1351, 2652
 Nakagami, H., 1472
 Nakagawa, T., 2864
 Nakajima, H., 1269
 Nakamura, T., 2094
 Nakao, K., 227, 1093, 1440, 2296
 Nakatsuka, S., 1012
 Namba, M., 1269
 Nanjo, K., 891, 2864
 Nanmo, T., 1269
 Nano, R., 1290
 Napoli, R., 2709
 Narbonne, H., 462
 Nardone, N.A., 593
 Natale, S., 1844
 Natali, A., 1807
 Natarajan, R., 1654
 Nathenson, S.G., 1992
 Nauck, M.A., 776, 2497
 Nauck, M.S., 776
 Naumann, C.M., 291
 Nawrocki, A., 1056
 Nawroth, P.P., 2792
 Neal, D., 1872
 Neal, D.W., 367, 558, 2487
 Negri, S., 77
 Nelson, B.A., 2419
 Nerup, J., 184, 1056
 Neschen, S., 2309
 Nesher, R., 308
 Netticadan, T., 2133
 Neville, D.M., Jr., 1227

Ng, E.H.C., 1004
 Nguyen, A., 39
 Nicaud, V., 1214
 Nicholls, A.J., 2047
 Nick, H., 515
 Nicklas, B.J., 2172
 Nielsen, P., 265
 Nielsen, S., 2301
 Nilsson, A., 2402
 Nishimura, H., 1093, 2296
 Nishimura, N., 1206
 Nishizawa, H., 2094
 Nisoli, E., 601
 Nitenberg, A., 1180
 Noël, G., 1531
 Nolte, L.A., 1397
 Nomura, A., 113
 Norrelund, H., 96
 Notkins, A.L., 2406
 Nuutila, P., 1371

O
 Oakes, N.D., 1158
 Oberson, A., 77
 Obici, S., 2786
 O'Brien, P., 947
 O'Brien, R.E., 329
 O'Brien, R.M., 502
 Oeser, J.K., 502
 Oeth, P., 886
 Ofrecio, J., 1344
 Ogata, M., 694
 Ogawa, Y., 227, 1093, 1440,
 2296
 Ogihara, T., 573, 1472
 Oh, H., 867
 Ohba, M., 255
 Ohlsson, C., 1539
 Ohue, M., 113
 Oikonen, V., 1371
 Oka, Y., 891, 1166
 Okita, M., 1206
 Oksanen, A., 1371
 Okuya, S., 1166
 Olefsky, J., 2316
 Olefsky, J.M., 139, 1344
 Olesen, M., 1588
 Oliver, R., 1983
 Olsen, G.S., 584
 Olsson, U., 2126
 Olszewski, S., 2029
 Oluwole, O.O., 1546
 Oluwole, S.F., 1546
 Omer, A., 1698
 O'Neill, J.J., 1698
 Onishi, Y., 573
 Ono, H., 573
 Oostra, B.A., 637
 Opawumi, D., 1918
 Op 't Eijnde, B., 18
 O'Rahilly, S., 686, 2199
 Orban, T., 1735
 Orho-Melander, M., 675, 2402
 Oriente, F., 1244
 Ornoy, A., 2521
 Ørntoft, T., 909
 O'Rourke, L., 955
 Ortmeier, H.K., 1126
 Ortolan, E., 752
 Ortsäter, H., 2737
 Osei-Hyiaman, D., 2169
 Östenson, C.-G., 1449

Osterhoff, M., 2641
 Ostrega, D.M., 2013
 Otani, A., 867
 Otani, K., 2013
 Otonkoski, T., 301
 Otsuka, M., 1012
 Ouchi, N., 2094
 Oxford, G.E., 2100
 Özçelikay, A.T., 455

P
 Pacini, G., 1539
 Pakkenberg, B., 1763
 Palacín, M., 2061
 Palm, F., 489
 Palmer, J.P., 1735
 Pamir, N., 1004
 Pamper, S., 143
 Pan, C.-Y., 2013
 Pan, D., 622
 Panthier, J.-J., 2021
 Panzenböck, U., 1643
 Paramore, D.S., 1911
 Parent, R.J., 1698
 Park, K.S., 2837
 Park, Y., 895
 Parker, A., 681
 Paroni, R., 496
 Parving, H.-H., 1214
 Pastor, R.L., 1706, 1983
 Patel, M.S., 2053
 Patterson, B.W., 1402
 Pauza, M.E., 39
 Pavlovic, D., 551
 Peakman, M., 1749
 Pearson, S.L., 1102
 Peck, A.B., 2100
 Pedersen, N.L., 2410
 Pedersen, O., 12, 690
 Pedersen, S.B., 12
 Pederson, R.A., 1004
 Pederson, T.M., 24
 Pellet, L., 2040
 Peltoniemi, P., 1371
 Pennefather, P.S., 1302
 Pennock, C.A., 2047
 Péraldi-Roux, S., 1311
 Perego, C., 1290
 Perego, L., 1290
 Perfetti, R., 785
 Permutt, M.A., 322, 681
 Pernet, A., 1618
 Perret, P., 1076
 Perretti, N., 1134
 Perrini, S., 2709
 Perrone, L., 2157
 Perry, G., 2792
 Perseghin, G., 277
 Perticone, F., 159
 Pérusse, L., 614, 697
 Peters, J.M., 2309
 Petersen, K.F., 1263
 Peterson, L.B., 2633
 Peterson-Wakeman, R., 166
 Pettiti, M., 1807
 Pfeiffer, A.F.H., 2641
 Phadke, S.A., 1482
 Phares, R.W., 436
 Philipson, L., 2472
 Phillips, B.G., 1119
 Phillips, M.S., 2633
 Phillips, S.L., 2114

Piceni Sereni, L., 277
 Pignata, C., 483
 Pigon, J., 1449
 Pihlajamäki, J., 2396
 Pijl, H., 2779
 Pileggi, A., 270, 1706, 1983
 Pincus, S.M., 1778
 Pipeleers, D., 551
 Pipeleers, D.G., 1, 1771
 Pizzuti, A., 831, 1950
 Pociot, F., 184, 1056
 Podestà, F., 175
 Podolin, D.A., 1186
 Poehlman, E.T., 91
 Poirier, O., 1214
 Poitout, V., 315, 2481, 2809
 Pokras, F., 444
 Pollin, T.L., 91
 Polonsky, K., 322
 Polonsky, K.S., 150, 1828, 2013,
 2472
 Pols, H.A.P., 637
 Polychronakos, C., 184
 Pontiroli, A.E., 1290
 Pontoglio, M., 2472
 Poot, M., 851
 Porat, M., 1425
 Pørksen, N., 776, 1778
 Portha, B., 1562
 Portocarrero, C.P., 1149
 Portolan, G., 2080
 Portugal, H., 462
 Post, C.M., 980
 Postic, C., 622
 Poulain, P., 2809
 Poulsen, P.L., 837
 Powers, W.J., 1911
 Pownall, H.J., 233
 Pozza, G., 277, 496, 2464
 Pralong, F.P., 2666
 Pratipanawat, T., 2572
 Pratipanawat, W., 2572
 Pratley, R.E., 1828
 Prentki, M., 803, 1970, 2237
 Previs, S.F., 1076
 Price, J.C., 2069
 Province, M.A., 614
 Pruschy, M., 2105
 Pugh, W., 2013
 Pugliese, A., 895
 Pulawa, L.K., 1064
 Pupilli, C., 985
 Purnell, J.Q., 1714

Q
 Quinn, A., 2459
 Quiñones-Galvan, A., 1807

R
 Raap, A., 797
 Rabbone, I., 483
 Rabinovitch, A., 710
 Rachdi, L., 2021
 Rafaeloff-Phail, R., 2822
 Rajas, F., 740
 Rajotte, R.V., 710
 Ramenghi, U., 483
 Ramal, T., 1464
 Ranalli, M., 1290
 Rankinen, T., 697
 Rao, D.C., 614, 697
 Raoux, S., 1214
 Rask-Madsen, C., 2611

Rattigan, S., 2659, 2682
 Ravussin, E., 707
 Reach, G., 2809
 Reddy, V., 2752
 Reed, L.J., 2329
 Reggio, H., 1311
 Reichart, D., 2316
 Reid, H., 1618
 Reijngoud, D.-J., 2591
 Reimann, F., 2253
 Reimann, M., 2641
 Reitman, M.L., 1440
 Renard, E., 2164
 Reneland, R., 690
 Renier, G., 660
 Rennich, J.S., 675, 681
 Resnick, H.E., 2384
 Reynisdottir, S., 1604
 Reynolds, T.H., 593
 Rhodes, C. J., 1791, 2029, 2181,
 2237
 Ribeiro, M., 1706
 Ribes, G., 1311
 Rice, S.Q.J., 937
 Rice, T., 614
 Rich, S.S., 861
 Richard, A.-M., 56
 Richter, E.A., 18, 265
 Richter, W., 1976
 Ricordi, C., 270, 895, 1706, 1983
 Riesenberg, K., 1425
 Rigalleau, V., 727
 Rimm, E.B., 2390
 Riou, J.-P., 1134
 Rissanen, J., 1949
 Ristow, M., 2641
 Ritov, V.B., 1253
 Ritter, S., 2831
 Ritzel, R., 776
 Rizza, R.A., 565, 747, 1351
 Robertson, R.P., 47, 2481
 Robinson, K.A., 2419
 Roden, M., 392, 2309
 Roduit, R., 1970
 Roep, B.O., 1749
 Roepstorff, P., 1056
 Rohner-Jeanrenaud, F., 601
 Romeo, G., 175
 Romijn, J.A., 2585, 2591, 2779
 Rondinone, C.M., 24
 Rönnumaa, T., 1371
 Ronner, P., 291
 Ronningen, K.S., 184, 2879
 Rook, S.L., 444
 Rosenbaum, T., 1755
 Rosenthal, J.M., 1618
 Rosner, P.J., 2029
 Ross, L., 2858
 Ross, R., 2349
 Rossetti, L., 348, 1872, 2786
 Rossini, A.A., 972
 Rössner, S., 1604
 Rouault, C., 2809
 Rouiller, D.G., 1039
 Routh, V.H., 2673
 Roy, S., 614
 Roye, M., 1311
 Ruan, H., 233
 Rubens, M.B., 652
 Rudich, A., 1425
 Russell, R.R., III, 1076
 Russo, G., 667

Rutter, G.A., 361
 Ryan, A.S., 2172
 Ryan, E.A., 710
 Ryan, L., 2842
 Ryder, J.W., 1149

S
 Saccomando, J., 2487
 Saccucci, F., 752
 Sachs, R., 1180
 Safai, B., 2363
 Sahai, A., 1482
 Saitta, A., 667
 Sakai, K., 32
 Sakata, T., 376, 385
 Sakoda, H., 573
 Salapatek, A. M. F., 1302
 Salmivirta, M., 2126
 Salt, I.P., 2148
 Salzmann, M.B., 2047
 Sampson, S.R., 255
 Sánchez, R.M., 1883
 Sánchez-Soto, M.C., 1755
 Sanders, N.M., 2831
 Sandqvist, M.M., 2344
 Sanke, T., 891, 2864
 Santagati, M.G., 1950
 Santopietro, S., 1244
 Santoro, N., 2157
 Sardella, A., 667
 Saris, W.H.M., 2548, 2870
 Sarvetnick, N., 2459
 Sasaoka, T., 1083, 1891
 Satchell, S.C., 2047
 Satin, L.S., 992, 2192
 Sato, Y., 1166
 Satoh, S., 1455
 Saudek, C.D., 2883
 Sauser, C., 77
 Savage, D.B., 2199
 Savola, K., 2625
 Sawcer, S., 184
 Sawtell, P.A., 2858
 Sblendido, M., 496
 Scarim, A.L., 283
 Schaar, G., 2870
 Schaeppi, M., 329
 Schalling, M., 2410
 Schally, A.V., 1110
 Scharfmann, R., 1219, 1571, 2021
 Schatz, M., 1612
 Scheek, L.M., 652
 Scheel, D., 928
 Schick, F., 2579
 Schiekofer, S., 2792
 Schlaeffer, F., 1425
 Schleicher, E., 2792
 Schmidova, K., 1714
 Schmidt, A.-M., 2792
 Schmiegel, W.H., 776, 2497
 Schmitz, O., 12, 776, 1778
 Schmitz-Peiffer, C., 2210
 Schneiter, P., 727
 Schorderet, D.F., 77
 Schow, S.R., 824
 Schrauwen, P., 2870
 Schreyer, S.A., 2555
 Schröder, H.D., 1324
 Schuit, F., 361
 Schuit, F.C., 1
 Schulte, M., 776

Schumann, W.C., 1872
 Schwaninger, M., 2792
 Schwarz, P.E.H., 694
 Schwenk, F.W., 565
 Schwenk, W.F., 1351
 Scirpoli, M., 2464
 Scott, L.J., 2842
 Scott, S., 1047
 Screenan, S., 2472
 Seal, L.J., 2540
 Seaquist, E.R., 2203
 Secchi, A., 277, 496, 2464
 See, W., 404
 Segal, D.G., 2199
 Segel, S.A., 1911
 Segu, V.B.G., 315
 Seino, S., 891
 Seino, Y., 891
 Sekihara, H., 1455
 Sel'ine, N., 573
 Senft, M., 462
 Sengenès, C., 2080
 Sengul, S., 2410
 Seppälä-Lindroos, A., 2337
 Sercarz, E., 2459
 Sergeev, P., 1683
 Serra, R., 601
 Serreze, D., 980, 2451
 Serreze, D.V., 763, 1992
 Serup, P., 1553
 Sesti, G., 1290
 Sewter, C.P., 2199
 Sha, L., 51
 Shafrir, E., 584
 Shah, P., 565, 1351
 Shapiro, A.M.J., 710
 Sharp, G.W.G., 329
 Shatford, J., 184
 She, J.-X., 2406
 Shen, S., 255
 Shepherd, P.R., 955
 Shepherd, R.M., 329
 Sherck, S.M., 2487
 Sherwood, S.J., 1495
 Shi, S., 824
 Shield, J.P., 184
 Shih, D.Q., 2472
 Shike, T., 1943
 Shimajiri, Y., 2864
 Shimizu, T., 2438
 Shimomura, I., 2094
 Shin, P., 83
 Shintani, M., 227, 1093, 1440, 2296
 Shiota, M., 367, 622, 2487
 Shirai, T., 1943
 Shojima, N., 573
 Short, K.R., 2652
 Shuldiner, A.R., 91, 2172
 Shulman, G.I., 1076, 1263
 Silveira, P., 1992
 Silverstein, J., 733
 Simmons, A., 1618
 Simmons, R.A., 2279
 Simoneau, J.-A., 195
 Singh, B., 2451, 2459
 Singh, L.P., 2355
 Sinopoli, F., 159
 Sironi, A.M., 1807
 Sironi, L., 1522
 Sivitz, W.L., 1119
 Sizyakov, G., 1627

Sjögren, K., 1539
 Skau, M., 1763
 Skelly, R.H., 1791
 Skorecki, K.L., 1691
 Slosberg, E.D., 1813, 2287
 Small, C.J., 248, 248, 2540
 Smith, G., 2641
 Smith, M., 2792
 Smith, S.B., 928
 Smith, V., 2763
 Smyth, C.A., 1227
 Snieder, H., 2858
 Socci, C., 277
 Sodhi, C.P., 1482
 Söhlein, P., 1976
 Somwar, R., 1464
 Song, F., 2053
 Song, S., 515
 Song, X.M., 1149, 2770
 Song, Z., 2673
 Spampinato, D., 831, 1950
 Spector, T.D., 2858
 Spevak, W.R., 824
 Spiller, D., 2431
 Spinias, G.A., 69, 1683, 2105
 Spranger, J., 2641
 Spravchikov, N., 1627
 Squadrito, F., 667
 Squadrito, G., 667
 Sreenan, S.K., 2013
 Srinivasan, M., 2053
 St. Denny, I., 1813
 Stadelmaier, B.T., 502
 Staehr, P., 1324, 1363
 Staels, B., 2809
 Stafford, D., 322
 Stampfer, M.J., 2390
 Stangé, G., 551
 Stanier, P., 199
 Stanley, C.A., 322
 Stanley, S.A., 248, 2540
 Stavrou, S., 1227
 Steenkiste, A.R., 1857
 Stefan, N., 882, 1143, 2161
 Stefanelli, C., 1580
 Stefanoni, N., 727
 Steiner, D.F., 534
 Stene, L.C., 2879
 Stephan, Z., 2287
 Stern, D.M., 2792
 Stevenson, R.W., 593
 Stewart, A.F., 2752
 Stickland, M.H., 1505, 2646
 Stingl, H., 392
 Stoffel, M., 2472
 Stoffers, D.A., 1553
 St-Onge, J., 195
 Stogaard, H., 2770
 Straub, S.G., 329
 Straume, M., 2001
 Strotmeyer, E.S., 1857
 Stumvoll, M., 876, 882, 1143, 2161, 2579
 Sturgis, L., 1495
 Suarez, B.K., 681
 Suckling, J., 1618
 Sugden, M.C., 2729
 Sugihara, H., 2438
 Sun, Y., 1047
 Surico, N., 985
 Sutherland, C., 937
 Sutherland, D.E.R., 47

Suzuki, L.A., 851
 Suzuma, I., 444
 Suzuma, K., 444
 Svensson, H., 2225
 Svensson, L., 1539
 Svenstrup, K., 1553
 Svetlanov, A., 980
 Svitek, C.A., 502
 Sweeney, G., 1464
 Swenberger, J.R., 1389
 Szczepaniak, L.S., 123
 Szurszewski, J.H., 51
 Szwergold, B.S., 2139

T
 Taheri, S., 2540
 Tai, T.-Y., 2598
 Takagi, H., 867
 Takahashi, M., 2094
 Takala, T.O., 1371
 Takane, K.K., 2752
 Takano, A., 1083, 1891
 Takasu, N., 2864
 Takata, Y., 1083
 Takaya, K., 227
 Takeda, J., 891
 Tamemoto, H., 1455
 Tamura, H., 2438
 Tamura, S., 1269
 Tanabe, K., 1166
 Tanaka, Y., 2481
 Tang, J., 1938
 Tang, S., 83
 Tang-Christensen, M., 2530
 Taniyama, Y., 1472
 Tanizawa, Y., 1166
 Tao, Q., 992
 Tappy, L., 727
 Tarnow, L., 1214
 Tassi, V., 1950
 Tataranni, P.A., 707, 901
 Tay, A., 455
 Taylor, R., 1102
 Tchernof, A., 91
 Teague, J., 992
 Teigeler, A., 882
 Templeton, L.J., 2279
 Temsah, R.M., 2133
 Tennenbaum, T., 255, 1627
 Terauchi, Y., 1455
 ter Harmsel, A., 2591
 Terruzzi, I., 277
 Teruel, T., 2563
 Testar, X., 2061
 Testers, L., 637
 Tetzeloff, G.G., 1330
 Thalén, P.G., 1158
 Thearle, M., 2268
 Theofilopoulos, A.N., 184
 Thomas, F.T., 1227
 Thomas, H.E., 2744
 Thomas, J., 681
 Thomas, J.D., 675
 Thomas, J.M., 1227
 Thomas, M.J., 1021
 Thomas, M.K., 521
 Thorell, A., 921
 Thorens, B., 1282, 1720
 Thörne, A., 1604
 Thornton, P.S., 322, 2763
 Tian, Y., 2505
 Tilton, R.G., 1495

Timsit, J., 1211
 Tirosch, A., 1425
 Tisch, R., 2459
 Tkac, I., 2203
 Toav, D.K., 824
 Tobe, K., 1455
 Todd, J.A., 184, 1200, 2633
 Toffolo, G., 150
 Tomassetti, S., 1844
 Tomino, Y., 1943
 Tonello, C., 601
 Topp, B.G., 1021
 Törnell, J., 1539
 Tornheim, K., 56
 Torp-Pedersen, C., 2611
 Torre, V., 667
 Toschi, E., 1807
 Tourrel, C., 1562
 Toyosawa, K., 113
 Tracy, R.P., 2384
 Tree, T.L., 1749
 Tremblay, F., 1901
 Tremoli, E., 1522
 Trencia, A., 1244
 Tribillac, F., 1311
 Trischitta, V., 831, 1950
 Tritschler, H., 2792
 Tschöp, M., 707
 Tse, C.A., 1821
 Tsuji, Y., 1455
 Tsushima, R.G., 1302
 Tu, A.-Y., 1851
 Tucker, M.Z., 1389
 Tuomilehto, J., 184, 886
 Tuomilehto-Wolf, E., 184
 Turcotte, L.P., 1389
 Turner, A.N., 91
 Tyrberg, B., 301
 Tzeng, T.-F., 2815
 Tzukerman, M., 1691

U
 Ueno, E., 1083, 1891
 Ueno, N., 1206
 Uffelman, K.D., 1402
 Underwood, S.R., 652
 Undlien, D.E., 184
 Uno, S., 1269
 Uno, T., 1083, 1891
 Urna, G., 667
 Ursø, B., 18
 Usellini, L., 1290
 Ustinov, J., 301
 Usui, I., 1083, 1891

V
 Vaag, A., 2770
 Vaessen, N., 637
 Vähäsalo, P., 2625
 Valensi, F., 1180
 Valle, T.T., 886
 Vallejo, M., 521
 van Baak, M.A., 2548
 Van Cauwenberge, A., 143
 Vanderheyden, I., 143
 Van Der Smissen, P., 143
 van Duijn, C.M., 637
 van Endert, P., 1749

Van Gent, T., 652
 van Heek, M., 1330
 Van Huyen, J.P.D., 1069
 Vanounou, S., 1425
 van Rossum, E.F.C., 2172
 Van Schaftingen, E., 1531
 Van Tol, A., 652
 Vasavada, R.C., 2752
 Vaulont, S., 1515
 Vaxillaire, M., 1219
 Vázquez, M., 1883
 Vega, N., 1134
 Vehkavaara, S., 2337
 Veldhuis, J.D., 1778, 2001
 Vella, A., 565, 1351
 Ventura, G., 159
 Venturini, M., 496
 Verchere, C.B., 534
 Vestbo, E., 630
 Vettor, R., 601
 Viallettes, B., 462
 Vidal, H., 1134
 Vidal, J., 2514
 Vidal-Puig, A., 2199
 Videen, T.O., 1911
 Vigliotta, G., 1244
 Vigneri, R., 831, 1950
 Vigouroux, C., 1378
 Villar, H.O., 824
 Vilboll, T., 609
 Viollet, B., 1515
 Vionnet, N., 1214
 Virkamäki, A., 2337
 Vizzardelli, C., 270, 1983
 Vlassara, H., 1214
 Vogel, M., 1976
 Volk, A., 882
 von Herrath, M., 39, 2459
 von Herrath, M.G., 2700
 Voshol, P.J., 2585, 2779
 Voss, M.C., 1056
 Vranic, M., 1402

W
 Wagenknecht, L.E., 861
 Wagenmakers, A.J.M., 2548
 Wagner, L., 2309
 Waguri, M., 1269
 Wahl, H.G., 876
 Wakabayashi, I., 2438
 Wakeling, E.L., 199
 Waldhäusl, W., 392, 2309
 Walker, E.A., 2883
 Walker, J., 2858
 Wallenius, K., 1539
 Wallis, M.G., 2659
 Wang, F., 2514
 Wang, H., 1949
 Wang, J., 63, 515, 534, 928, 2786
 Wang, R., 166
 Wang, S.P., 1970
 Wang, Y., 1821
 Wang, Z., 166
 Wareham, N.J., 686
 Warnock, G.L., 710
 Warram, J.H., 204, 2842
 Warwar, N., 308
 Wasserfall, C., 515

Wasson, J.C., 681
 Watada, H., 928
 Watanabe, R.M., 886
 Watanabe, T., 376, 385
 Watkins, S., 817
 Watson, D.G., 411
 Weber, M., 1683
 Wegmann, D., 1274, 2459
 Wegmann, D.R., 1729
 Weigle, B., 2792
 Weigle, D.S., 1714
 Weir, G.C., 1698, 2709
 Weiser, P., 972
 Weisnagel, S.J., 697
 Weiss, R., 1193
 Weisser, M., 2161
 Weissleder, R., 2231
 Weksler-Zangen, S., 2521
 Welsh, E.M., 2001
 Welsh, K., 1200
 Wen, L., 2459
 Wertheimer, E., 255, 1627
 Westerlund, J., 51, 1785
 Weyer, C., 707, 1828
 Whalen, B.J., 972
 Wheeler, M.B., 1302
 White, M., 2431
 White, M.F., 2164
 Whiteside, C.I., 2376
 Wick, M.M., 824
 Wicker, L.S., 2633
 Wicksteed, B., 1791
 Wiegman, C.H., 2591
 Willett, W.C., 2390
 Williams, G., 105, 2431
 Williams, K.V., 2069
 Williams, P.E., 2487
 Williams, S.C.R., 1618
 Wilson, C., 1828
 Wilson, M.C., 361
 Wilson, S., 105
 Winkler, C., 1211
 Wintersperger, A., 1643
 Winzell, M.S., 2225
 Wisse, B.E., 1714
 Witteman, J.C.M., 637
 Wojtazewski, J.F.P., 265
 Wolf, B.A., 2721
 Wolfe, T., 39, 2700
 Wollheim, C.B., 1039, 1311
 Wordsworth, P., 184
 Wortel, J., 1237
 Wren, A.M., 2540
 Wright, C., 785
 Wu, L., 166
 Wu, Y., 1110

X
 Xie, J., 2406
 Xu, A., 1821
 Xu, F., 1302
 Xu, G., 353
 Xu, J., 534

Y
 Yagil, C., 2521
 Yagil, Y., 2521
 Yáñez, L., 1618

Yakar, S., 1110
 Yamada, H., 1012
 Yamada, N., 891
 Yamagata, K., 891, 1269
 Yamagishi, S.-i., 1491
 Yamamoto, A., 1012
 Yamamoto, K., 1269, 1472
 Yamamoto, Y., 1093
 Yaney, G.C., 56
 Yang, C., 2598
 Yang, D., 2001
 Yang, X.-J., 733
 Yang, X.M., 348
 Yang, Y., 2691
 Yaniv, M., 2472
 Yarasheski, K.E., 1397
 Yasuda, K., 891
 Yaworsky, K., 1464
 Ye, J., 1821
 Ye, J.-M., 411
 Yeaman, S.J., 720, 955, 1102
 Yee, A.J., 1389
 Yeh, C.-H., 1495
 Yki-Järvinen, H., 1371, 2337
 Yokoi, N., 891
 Yonemitsu, S., 1093, 2296
 Yoon, J.-W., 2691
 Yorek, M.A., 1927
 Yoshimasa, Y., 1440
 Yoshimatsu, H., 376, 385
 Yoshimura, S.-i., 1472
 Yoshimura, Y., 1992
 Youd, J.M., 2659
 Youn, J.H., 418
 Young, L.H., 1076
 Youngren, J.F., 2323
 Yu, C., 1263
 Yu, H., 2169
 Yu, J.G., 1344
 Yu, L., 1274, 1735
 Yu, M., 1149

Z
 Zagury, J.-F., 1211
 Zaitsev, S.V., 797
 Zangen, D.H., 2521
 Zechner, R., 1643, 2585
 Zekzer, D., 2459
 Zeller, M., 895
 Zelles, T., 2100
 Zennaro, C., 2619
 Zethelius, B., 690
 Zhang, B.B., 2323
 Zhang, M., 2192
 Zhang, X.-N., 1495
 Zhao, C., 361
 Zhiming, Z., 2169
 Zhiyin, R., 2169
 Zhou, Y.-P., 2013
 Zierath, J.R., 1149, 2770
 Zimmerman, E.F., 1193
 Zimmerman, R., 1643
 Zitoun, C., 740
 Ziv, E., 584
 Zorzano, A., 2061
 Zulewski, H., 521

